[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 615
1. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ: Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol; 2009 Oct;36(7):779-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
  • The purpose of this study was to compare the diagnostic value of positron emission tomography (PET) using [(18)F]-fluorodeoxyglucose ((18)F-FDG) and O-(2-[(18)F]fluoroethyl)-l-tyrosine ((18)F-FET) in patients with brain lesions suspicious of cerebral gliomas.
  • METHODS: Fifty-two patients with suspicion of cerebral glioma were included in this study.
  • The cerebral accumulation of (18)F-FDG was calculated by decay corrected subtraction of the (18)F-FET scan from the (18)F-FET/(18)F-FDG scan.
  • RESULTS: Histology revealed 24 low-grade gliomas (LGG) of World Health Organization (WHO) Grade II and 19 high-grade gliomas (HGG) of WHO Grade III or IV, as well as nine others, mainly benign histologies.
  • The gliomas showed increased (18)F-FET uptake (>normal brain) in 86% and increased (18)F-FDG uptake (>white matter) in 35%. (18)F-FET PET provided diagnostically useful delineation of tumor extent while this was impractical with (18)F-FDG due to high tracer uptake in the gray matter.
  • A local maximum in the tumor area for biopsy guidance could be identified with (18)F-FET in 76% and with (18)F-FDG in 28%.
  • In some benign lesions like abscesses, increased uptake was observed for both tracers indicating a limited specificity of both techniques.
  • CONCLUSIONS: (18)F-FET PET is superior to (18)F-FDG for biopsy guidance and treatment planning of cerebral gliomas.
  • The uptake of (18)F-FDG is associated with prognosis, but the predictive value is limited and a histological evaluation of tumor tissue remains necessary.
  • Therefore, amino acids like (18)F-FET are the preferred PET tracers for the clinical management of cerebral gliomas.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Tyrosine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19720290.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / O-(2-fluoroethyl)tyrosine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42HK56048U / Tyrosine
  •  go-up   go-down


2. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Elia AE, Shih HA, Loeffler JS: Stereotactic radiation treatment for benign meningiomas. Neurosurg Focus; 2007;23(4):E5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation treatment for benign meningiomas.
  • Meningiomas are the second most common primary tumor of the brain.
  • For incompletely resected or inoperable benign meningiomas, 3D conformal external-beam radiation therapy can provide durable local tumor control in 90 to 95% of cases.
  • Although SRS has longer follow-up than SRT, both techniques have excellent 5-year tumor control rates of greater than 90% for benign meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961042.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


Advertisement
4. Fotopoulos AD, Alexiou GA, Goussia A, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, Tsiouris S: (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol; 2008 Sep;89(2):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index.
  • Meningiomas account for about 30% of all intracranial tumors.
  • We evaluated prospectively whether (99m)Tc-Tetrofosmin ((99m)Tc-TF) uptake in meningiomas correlates with cellular proliferative activity and with tumor grade.
  • Brain single-photon emission computed tomography (SPECT) by (99m)Tc-TF was performed within a week prior to surgical excision.
  • In the excised tumor specimens we assessed Ki-67 antigen expression.
  • 14 of 18 patients had benign meningiomas, while the remaining four had anaplastic meningiomas.
  • A significant correlation was found between both (99m)Tc-TF uptake and tumor grade (r = 0.722, P = 0.001) and between (99m)Tc-TF uptake and Ki-67 expression (r = 0.930, P < 0.001).
  • There was a significant correlation between the intensity of tracer uptake and tumor recurrence at 1 year postoperative (r = 0.574, P = 0.02).
  • This pilot study implies that (99m)Tc-TF brain SPECT could prove useful in differentiating benign from anaplastic meningiomas and is a potential indicator of their proliferative activity.
  • [MeSH-major] Brain / diagnostic imaging. Meningeal Neoplasms / diagnostic imaging. Meningioma / diagnostic imaging. Technetium Tc 99m Sestamibi. Tomography, Emission-Computed, Single-Photon

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):209-14 [15072469.001]
  • [Cites] Adv Anat Pathol. 2005 May;12(3):144-8 [15900115.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Nov;52(6):609-18 [8229080.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Eur J Nucl Med. 1996 Nov;23 (11):1478-84 [8854846.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):494-7; discussion 497-8 [1584346.001]
  • [Cites] Cancer. 1994 Oct 1;74(7):1921-6 [7521787.001]
  • [Cites] Nucl Med Biol. 2000 Apr;27(3):299-307 [10832087.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):970-5 [11567227.001]
  • [Cites] Nucl Med Commun. 2000 Sep;21(9):803-10 [11065152.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2091-4 [8254393.001]
  • [Cites] J Neurooncol. 2000;46(1):63-70 [10896206.001]
  • [Cites] Curr Opin Oncol. 1997 May;9(3):230-4 [9229144.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Aug;19(4):411-21 [15453956.001]
  • [Cites] Ann Nucl Med. 1997 Nov;11(4):285-90 [9460519.001]
  • [Cites] Nucl Med Commun. 1998 Feb;19(2):97-105 [9548192.001]
  • [Cites] J Nucl Cardiol. 1995 Jul-Aug;2(4):317-26 [9420806.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):989-93 [3409179.001]
  • [Cites] Neurosurgery. 1995 Sep;37(3):478-82; discussion 483 [7501113.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):820-7 [15785954.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):639-49 [12579319.001]
  • [Cites] Cancer. 1994 Dec 15;74(12):3176-89 [7982181.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2085-9 [8254391.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1036-44; discussion 1044-5 [7885547.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):373-85 [1503912.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):359-60 [17634740.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):357-61 [15702834.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):153-7 [9261740.001]
  • [Cites] Breast Cancer Res. 2004;6(2):R56-62 [14979918.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Jun;20(3):249-59 [15989470.001]
  • [Cites] Ann Nucl Med. 2007 Jul;21(5):293-8 [17634847.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(1):26-31; discussion 31-2 [9522904.001]
  • [Cites] Expert Rev Med Devices. 2005 Mar;2(2):191-6 [16293055.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):207-8 [16575536.001]
  • [Cites] Neuro Oncol. 2008 Feb;10 (1):104-5 [18055861.001]
  • [Cites] J Nucl Med. 1998 May;39(5):802-6 [9591579.001]
  • (PMID = 18458817.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


5. Pear WS: New roles for Notch in tuberous sclerosis. J Clin Invest; 2010 Jan;120(1):84-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex (TSC) is a dominantly inherited disease that is characterized by the growth of multiple benign tumors that are often difficult to treat.
  • Furthermore, studies in tumor cells suggest that inhibiting Notch slows growth of the tumor cells.
  • Although much remains to be learned about the precise mechanisms by which TSC loss leads to Notch activation, the newly identified link of TSC to Notch provides the rationale for testing Notch inhibitors in TSC-associated tumors.
  • [MeSH-minor] Animals. Basic Helix-Loop-Helix Transcription Factors / physiology. Homeodomain Proteins / physiology. Humans. Monomeric GTP-Binding Proteins / physiology. Neoplasms / etiology. Neuropeptides / physiology. Protein Kinases / physiology. TOR Serine-Threonine Kinases. Transcription Factors / physiology. Tumor Suppressor Proteins / physiology

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] J Clin Invest. 2010 Jan;120(1):103-14 [20038814.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):491-500 [12547707.001]
  • [Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):584-6 [12773160.001]
  • [Cites] Curr Opin Cell Biol. 2004 Apr;16(2):195-205 [15196564.001]
  • [Cites] Cell. 1994 Feb 11;76(3):415-8 [8313463.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] J Clin Invest. 2010 Jan;120(1):93-102 [20038815.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Biochem J. 2008 Jun 1;412(2):179-90 [18466115.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):657-68 [18722871.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5314-7 [18765521.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(R1):R94-100 [19297407.001]
  • [Cites] Curr Opin Cell Biol. 2009 Apr;21(2):230-6 [19237273.001]
  • [CommentOn] J Clin Invest. 2010 Jan;120(1):93-102 [20038815.001]
  • [CommentOn] J Clin Invest. 2010 Jan;120(1):103-14 [20038814.001]
  • (PMID = 20038806.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / CRTC1 protein, human; 0 / Homeodomain Proteins; 0 / Neuropeptides; 0 / RHEB protein, human; 0 / Receptors, Notch; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 149348-15-2 / HES1 protein, human; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2798710
  •  go-up   go-down


6. Maillo A, Orfao A, Espinosa AB, Sayagués JM, Merino M, Sousa P, Lara M, Tabernero MD: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol; 2007 Oct;9(4):438-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
  • Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge.
  • In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas.
  • A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed.
  • From the prognostic point of view, losses of chromosomes 9, 10, 14, and 18 and del(1p36) were associated with a shorter RFS at 2.5, 5, and 10 years.
  • Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses.
  • In fact, coexistence of -14 and del(1p36) in the ancestral tumor cell clone, together with tumor size, represented the best combination of independent prognostic factors for the identification of those patients with a high risk of an early relapse.
  • Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):19-24 [1688296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):431-7 [9629361.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):271-5 [16634530.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):259-67 [11128617.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):101-4 [8548731.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg Sci. 1996 Mar;40(1):17-23 [8913957.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 1986 May;22(1):63-8 [3456829.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Neurochirurgie. 1986;32(2):129-34 [3724942.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Med Assoc Thai. 1997 Jul;80(7):473-8 [9277078.001]
  • (PMID = 17704362.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994101
  •  go-up   go-down


7. Sentürk S, Oğuz KK, Cila A: Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. Diagn Interv Radiol; 2009 Mar;15(1):3-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner.
  • PURPOSE: To determine whether there are statistically significant differences in cerebral blood volume (CBV) and cerebral blood flow (CBF) of brain tumors of different histopathologic types including primary and secondary benign and malignant lesions.
  • To determine whether these measurements relate to tumor grade.
  • MATERIALS AND METHODS: Forty-five patients with brain tumors, age 2 to 79 years, underwent dynamic contrast-enhanced susceptibility- weighted echo-planar perfusion magnetic resonance imaging (MRI) using a 3T MR scanner.
  • The lesions were evaluated by measurements of relative cerebral blood volume (rCBV) and relative cerebral blood flow (rCBF).
  • The Mann-Whitney U test was used to compare rCBV and rCBF measurements of tumor groups -- 13 low-grade and 13 high-grade neuroepithelial (NE) tumors, five metastases, 10 meningiomas, and four others.
  • Peritumoral rCBV and rCBF measurements of high grade NE tumors and metastases were also compared.
  • RESULTS: Measurements of rCBV and rCBF were statistically significantly higher (P < 0.05) in high-grade NE tumors than in low-grade NE tumors.
  • The difference was not statistically significant in comparing high-grade NE tumors with metastases and meningiomas.
  • Peritumoral rCBV of high-grade NE tumors was significantly higher than peritumoral rCBV of metastases (P < 0.05).
  • CONCLUSION: CBV and CBF measurements provided by 3T perfusion MRI can help to predict NE tumor grading preoperatively, and differentiate between primary brain tumors and metastases.
  • [MeSH-major] Brain / blood supply. Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Cerebrovascular Circulation. Image Enhancement / methods. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263367.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


8. Matsuo Y, Kamitani T: Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One; 2010;5(5):e10481
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes.
  • CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi.
  • Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Cell Line, Tumor. Female. Humans. MART-1 Antigen. Male. Melanins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Nevus / metabolism. Nevus / pathology. Pigmentation. Retinoblastoma / metabolism. Retinoblastoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Mar;54(3):196-200 [11253130.001]
  • [Cites] Neurology. 2009 Oct 20;73(16):1286-91 [19841380.001]
  • [Cites] J Neurosci. 2002 Apr 15;22(8):3090-9 [11943812.001]
  • [Cites] Nat Rev Neurosci. 2002 Jul;3(7):531-41 [12094209.001]
  • [Cites] Traffic. 2002 Sep;3(9):678-93 [12191019.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):217-23 [14991540.001]
  • [Cites] J Immunother. 1998 Jan;21(1):27-31 [9456433.001]
  • [Cites] Cancer. 1999 Feb 25;87(1):37-42 [10096358.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):617-27 [10440689.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):201-5 [15583688.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] J Cell Sci. 2005 Aug 1;118(Pt 15):3523-30 [16030137.001]
  • [Cites] Epidemiology. 2006 Sep;17(5):582-7 [16837822.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97 [17878918.001]
  • [Cites] Orphanet J Rare Dis. 2007;2:43 [17980020.001]
  • [Cites] Nat Clin Pract Oncol. 2009 Feb;6(2):105-17 [19107110.001]
  • [Cites] Virchows Arch. 2009 May;454(5):505-11 [19352698.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1792(7):616-24 [18955133.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1039-46 [11474288.001]
  • (PMID = 20463956.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG024497
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanins; 0 / Neoplasm Proteins; 0 / alpha-Synuclein
  • [Other-IDs] NLM/ PMC2864738
  •  go-up   go-down


9. Kondziolka D, Flickinger JC, Lunsford LD: The principles of skull base radiosurgery. Neurosurg Focus; 2008;24(5):E11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stereotactic radiosurgery is commonly used for selected patients with benign cranial base tumors.
  • The goal of radiosurgery is cessation of tumor growth and preservation of neurological function.
  • [MeSH-major] Cranial Irradiation / methods. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Brain Stem / physiopathology. Brain Stem / surgery. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Cranial Nerve Injuries / prevention & control. Decompression, Surgical. Diagnostic Imaging. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Patient Selection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


11. Niranjan A, Kondziolka D, Lunsford LD: Neoplastic transformation after radiosurgery or radiotherapy: risk and realities. Otolaryngol Clin North Am; 2009 Aug;42(4):717-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, the use of radiosurgery or radiotherapy for benign brain tumors has increased significantly.
  • Although long-term follow-up from several centers suggests that radiosurgery or radiotherapy is effective and safe, there are particular concerns regarding development of radiation-induced tumors.
  • This article reviews the use of radiosurgery and fractionated radiation therapy with particular regard to new tumor induction and malignant transformation.
  • The authors have found that the risk of radiation associated tumors after radiosurgery or radiotherapy for benign brain tumors is very low.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Cell Transformation, Neoplastic / pathology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Radiation-Induced / pathology. Radiosurgery / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751875.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


12. Lee DK, Cho KT, Im SH, Hong SK: Pleomorphic xanthoastrocytoma with an intracystic hemorrhage : a case report and literature review. J Korean Neurosurg Soc; 2007 Nov;42(5):410-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) has been considered as a low grade tumor of adolescents and young adults.
  • Although this tumor often shows cystic component, the hemorrhage within the cyst is extremely rare.
  • After gross total resection of the tumor, the patient was fully recovered from neurological deficit.
  • It is suggested that this typically benign tumor could be presented with hemorrhage, causing a rapid neurological deterioration.
  • Prompt surgical intervention, especially total removal of the tumor can provide an excellent functional recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):269-74 [8293186.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Nov-Dec;14(6):1397-404 [8279337.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):353-5 [1513442.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Neurosurgery. 2002 Oct;51(4):1079-82; discussion 1082 [12234421.001]
  • [Cites] Br J Radiol. 2001 Mar;74(879):270-2 [11338106.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):169-71 [15690134.001]
  • [Cites] Cancer. 1999 May 1;85(9):2033-45 [10223246.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Jan;17(1):154-6 [8770268.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):564-9 [8113873.001]
  • (PMID = 19096580.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588191
  • [Keywords] NOTNLM ; Cyst / Hemorrhage / Mural nodule / Pleomorphic xanthoastrocytoma (PXA)
  •  go-up   go-down


13. Mueller OM, van de Nes JA, Wieland R, Schoch B, Sure U: Surgical treatment of primary intracranial myxoma in a child following radiotherapy: case report and review of the literature. Childs Nerv Syst; 2010 Jun;26(6):829-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Myxomas are benign tumors of the mesenchymal origin and account for about half of the benign cardiac tumors.
  • As a secondary neoplasia following radiotherapy, myxoma has only been reported once in the literature.
  • The close relation to the radiation field of the posterior fossa makes it highly suggestive that the myxoma developed as a secondary neoplasia induced by radiotherapy.
  • Treatment philosophy for this benign tumor entity is a completed resection of the lesion with regular follow-up MRI.
  • [MeSH-major] Brain Neoplasms / diagnostic imaging. Brain Neoplasms / surgery. Medulloblastoma / radiotherapy. Myxoma / surgery. Neoplasms, Radiation-Induced / surgery
  • [MeSH-minor] Brain / pathology. Brain / surgery. Child. Combined Modality Therapy / methods. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Radiography. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Dent Res. 2008 Jan-Mar;19(1):62-5 [18245926.001]
  • [Cites] Acta Neurochir (Wien). 1995;136(3-4):117-26 [8748840.001]
  • [Cites] Neurosurgery. 1987 Feb;20(2):329-31 [3561744.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Apr;67(4):389-93 [12663111.001]
  • [Cites] Arch Neurol. 2007 Aug;64(8):1115-20 [17698701.001]
  • [Cites] Acta Neurochir (Wien). 2007;149(7):713-7 [17558455.001]
  • [Cites] Acta Neurochir (Wien). 2007 Nov;149(11):1157-62 [17906966.001]
  • [Cites] Surg Neurol. 2007;68 Suppl 2:S22-8 [18037039.001]
  • [Cites] Int J Cardiol. 2004 Sep;96(3):471-3 [15301902.001]
  • [Cites] J Neurol. 1992 Mar;239(3):170-4 [1573423.001]
  • [Cites] Neurol India. 2005 Jun;53(2):216-8 [16010063.001]
  • [Cites] Z Gesamte Inn Med. 1984 Aug 1;39(15):368-70 [6495798.001]
  • [Cites] Eur J Neurol. 2008 Dec;15(12 ):e112-3 [19049534.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Chest. 1978 Oct;74(4):451-2 [699660.001]
  • [Cites] Medicine (Baltimore). 2001 May;80(3):159-72 [11388092.001]
  • [Cites] Neuroradiology. 1992;34(1):57-61 [1553039.001]
  • [Cites] Neurology. 1981 Jan;31(1):8-13 [7192829.001]
  • [Cites] Neuroradiology. 1990;32(3):250-1 [2215912.001]
  • [Cites] J Neurosurg. 2006 Mar;104(3):440-3 [16572660.001]
  • [Cites] Stroke. 1988 Nov;19(11):1435-40 [3188128.001]
  • [Cites] Int J Cardiol. 1994 Jun 15;45(2):144-6 [7960255.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):166-9; discussion 169-70 [10414581.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):945-7; discussion 947-8 [11322458.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):453-5 [7835787.001]
  • [Cites] Ann Surg. 1948 May;127(4):706-19 [18917127.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1978 Dec;41(12):1119-24 [366086.001]
  • [Cites] Cancer Radiother. 2000 Nov-Dec;4(6):469-72 [11191855.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] J Radiol. 1993 Mar;74(3):147-50 [8496843.001]
  • [Cites] J Neurooncol. 2008 Jun;88(2):157-60 [18320140.001]
  • (PMID = 19946690.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 32
  •  go-up   go-down


14. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


15. Zhang QF, Liu DL, Yang ZQ: [Surgical treatment of tumors in anterior and middle skull base by modified maxillary bone disassembly procedures]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Nov;41(11):840-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of tumors in anterior and middle skull base by modified maxillary bone disassembly procedures].
  • OBJECTIVE: To explore the therapeutic effect of the modified maxillary bone disassembly procedures on patients with tumors in the anterior and middle skull base.
  • Ten tumors in the anterior and middle skull base were resected according to the pathology, size and site of the skull base tumors including 9 benign tumors and 1 malignant tumor.
  • RESULTS: All tumors were resected completely.
  • The patients with benign tumors showed no recurrence .
  • One patient with melanoma died of brain metastase.
  • CONCLUSIONS: It is necessary to estimate the tumors thoroughly before surgery.
  • According to the location of the tumor, the modified maxillary bone disassembly is the nearest and harmless approach, through which the tumors can be completely excised with minimal invasiveness.
  • [MeSH-major] Maxilla / surgery. Skull Base Neoplasms / surgery. Surgery, Oral / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283538.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • Genetic Alliance. consumer health - Brain Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


17. Moliterno JA, Sood S, Zambrano E, Kim JH, Piepmeier JM, Baehring JM: Intracranial benign fibrous histiocytomas: a case report and review. J Neurooncol; 2009 Apr;92(2):203-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial benign fibrous histiocytomas: a case report and review.
  • Although there have been several reports about malignant fibrous histiocytomas, less is known about the benign variant of these intracranial tumors as they are often misclassified as other types of tumors.
  • Pathology revealed benign fibrous histiocytoma.
  • We also review other cases reported in the literature in an effort to provide further insight into the diagnosis and management of this rare tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):215-8 [10682930.001]
  • [Cites] Acta Neurochir (Wien). 2006 Jan;148(1):73-6; discussion 76 [16200478.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Oct;30(10 ):759-62 [1708451.001]
  • [Cites] Clin Neuropathol. 2002 May-Jun;21(3):93-8 [12049182.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):284-93 [7681032.001]
  • [Cites] Acta Neuropathol. 1973 Feb 19;23(3):187-99 [4348056.001]
  • [Cites] Surg Neurol. 1988 Jan;29(1):27-31 [3336836.001]
  • [Cites] No Shinkei Geka. 1984 Apr;12 (5):641-8 [6087179.001]
  • [Cites] J Neurooncol. 2001 Apr;52(2):157-60 [11508815.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] J Neurooncol. 2000 Aug;49(1):9-17 [11131990.001]
  • [Cites] No Shinkei Geka. 1991 Mar;19(3):267-71 [2038418.001]
  • (PMID = 19030779.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


18. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, Reeder JE: Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol; 2005 Jun;166(6):1807-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After an initial response in most patients, tumors invariably progress to an androgen-independent state.
  • Using immunohistochemistry, we show that interleukin-8 was expressed by the neuroendocrine tumor cells in human prostate cancer tissue.
  • Expression of the interleukin-8 receptor CXCR1 was negative or low in benign prostatic tissue and was frequently increased in malignant cells of high-grade prostatic intraepithelial neoplasia and prostate cancer; however, CXCR1 was not detected in the neuroendocrine tumor cells, suggesting a paracrine mechanism by which interleukin-8 produced by neuroendocrine tumor cells stimulates androgen-independent proliferation of prostate cancer.
  • Neuroendocrine tumor cells expressed another type of interleukin-8 receptor, CXCR2, suggesting an autocrine mechanism by which interleukin-8 regulates the differentiation or function of the neuroendocrine cells.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Interleukin-8 / biosynthesis. Prostatic Neoplasms / pathology. Receptors, Interleukin-8A / biosynthesis. Receptors, Interleukin-8B / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1991 Sep 13;253(5025):1280-3 [1891716.001]
  • [Cites] Science. 1991 Sep 13;253(5025):1278-80 [1840701.001]
  • [Cites] Chem Immunol. 1992;51:236-65 [1567543.001]
  • [Cites] Cancer. 1992 Jul 1;70(1 Suppl):254-68 [1350941.001]
  • [Cites] J Immunol. 1992 Oct 1;149(7):2358-66 [1382099.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1798-801 [1281554.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):1338-42 [8419336.001]
  • [Cites] Brain Res. 1993 Jan 8;600(1):49-55 [8422590.001]
  • [Cites] J Urol. 1993 May;149(5):1209-13 [8097794.001]
  • [Cites] Biochem J. 1993 Aug 15;294 ( Pt 1):285-92 [8363581.001]
  • [Cites] FEBS Lett. 1994 Mar 21;341(2-3):187-92 [8137938.001]
  • [Cites] Verh Dtsch Ges Pathol. 1993;77:107-10 [7511265.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jun;118(6):616-8 [8204007.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5474-8 [7522959.001]
  • [Cites] Eur Urol. 1995;27 Suppl 2:45-7 [7750532.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Prostate Suppl. 1996;6:3-8 [8630226.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):910-6 [8826857.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2882-90 [9058825.001]
  • [Cites] Curr Biol. 1997 Feb 1;7(2):112-21 [9024623.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):450-9 [9092797.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Eur J Immunol. 1998 Jan;28(1):164-70 [9485196.001]
  • [Cites] Urology. 1998 Apr;51(4):585-9 [9586611.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7379-84 [9636157.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4640-5 [9788616.001]
  • [Cites] Urology. 1999 Jan;53(1):139-47 [9886603.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):8316-21 [10075738.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] Prostate. 1999 Oct 1;41(2):78-88 [10477904.001]
  • [Cites] Eur Urol. 2005 Feb;47(2):147-55 [15661408.001]
  • [Cites] Prostate. 2000 Mar 1;42(4):274-9 [10679756.001]
  • [Cites] Endocrine. 1999 Oct;11(2):195-202 [10709768.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2104-19 [10815938.001]
  • [Cites] Pathol Res Pract. 2000;196(5):277-84 [10834383.001]
  • [Cites] J Urol. 2000 Oct;164(4):1420-5 [10992426.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):313-35 [11544102.001]
  • [Cites] Am J Clin Pathol. 2002 Sep;118(3):408-17 [12219783.001]
  • [Cites] Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9 [12231070.001]
  • [Cites] Trends Pharmacol Sci. 2002 Oct;23(10):459-67 [12368070.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6039-44 [12414626.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 2):S36-40 [14713751.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2197-205 [14767470.001]
  • [Cites] Technol Cancer Res Treat. 2004 Oct;3(5):411 [15453805.001]
  • [Cites] Pathol Res Pract. 1987 Jun;182(3):298-307 [2442732.001]
  • [Cites] Prostate. 1989;14(2):103-15 [2710689.001]
  • [Cites] Pathol Res Pract. 1989 Sep;185(3):373-80 [2813190.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Dec 14;173(2):534-40 [2260966.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):287-96 [1313390.001]
  • (PMID = 15920165.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  • [Other-IDs] NLM/ PMC1602414
  •  go-up   go-down


19. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • More intensive staining of cathepsin B in these tumors was not only found at the tumor front, but also in the invading pseudopodia of a single migrating tumor cells.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult


20. Ito E, Saito K, Nagatani T, Ishiyama J, Terada K, Yoshida M, Wakabayashi T: Intradural cranial chordoma. World Neurosurg; 2010 Mar;73(3):194-7; discussion e31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Intradural chordomas are rare and have been considered benign owing to the feasibility of complete resection and the display of lesser aggressive biologic behavior than typical chordomas.
  • A tumor (anti-Ki-67 monoclonal antibody [MIB-1], 13.9%) in a 59-year-old woman was strongly adherent to the brainstem and involved the basilar artery and its branches.
  • After subtotal removal, the remnant tumor was treated with stereotactic radiotherapy.
  • A tumor (MIB-1, 6.2%) in a 75-year-old woman repeatedly recurred even after initial gross total removal.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Chordoma / diagnosis. Chordoma / therapy. Dura Mater

  • Genetic Alliance. consumer health - Chordoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20860957.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • The present study was carried out on a total of 79 archival cases of ependymal tumors in addition to a variety of other primary CNS tumors.
  • Upon comparing with other CNS tumors (41 cases), it was found that CD99 could differentiate between ependymomas and nonependymal tumors, but intensity and pattern of staining were of no consequence in determining variant type or degree of histologic aggressiveness.
  • Thus, EMA was found to be of little value in the diagnosis of ependymoma and in the differentiation between different types and grades.
  • CD99 can hence be recommended for use as a good marker for differentiation between ependymal and other CNS tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


22. Ramina R, Neto MC, Fernandes YB, Aguiar PH, de Meneses MS, Torres LF: Meningiomas of the jugular foramen. Neurosurg Rev; 2006 Jan;29(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is controversy regarding the management of these tumors.
  • From a series of 107 patients that had been operated on for jugular foramen tumors between 1987 and 2005, ten had meningiomas.
  • A high incidence of malignant or aggressive tumors (six cases) was found.
  • Radical removal of benign jugular foramen meningiomas is possible.
  • The incidence of postoperative deficit of cranial nerves is higher than in other benign tumors of the jugular foramen.
  • A high incidence of aggressive (malignant) tumors was observed in this series.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Skull Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1996 Jul;17(4):658-68 [8841718.001]
  • [Cites] Arq Neuropsiquiatr. 2004 Dec;62(4):997-1003 [15608958.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):373-7 [14736665.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Feb;106(2):128-36 [1738543.001]
  • [Cites] No Shinkei Geka. 1989 Jan;17 (1):87-92 [2651958.001]
  • [Cites] Otolaryngol Head Neck Surg (1979). 1979 Sep-Oct;87(5):578-83 [503520.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):647-52; discussion 652-3 [10949439.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):17-27 [7815129.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):903-9 [7472562.001]
  • [Cites] Laryngoscope. 2004 Jan;114(1):25-32 [14709990.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):279-84 [8545782.001]
  • [Cites] Laryngoscope. 1984 Jun;94(6):772-8 [6727514.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1576-7 [11075777.001]
  • [Cites] Am J Clin Pathol. 1989 Sep;92(3):266-72 [2476026.001]
  • [Cites] Neurosurg Focus. 2004 Aug 15;17(2):E5 [15329020.001]
  • [Cites] Otolaryngol Clin North Am. 1982 Nov;15(4):897-916 [6298686.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neurosurgery. 2005 Apr;56(2 Suppl):337-43; discussion 337-43 [15794830.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):624-7 [1374854.001]
  • [Cites] Cancer. 1975 Oct;36(4):1363-73 [1175134.001]
  • [Cites] Surg Neurol. 1998 Dec;50(6):563-70 [9870817.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1014-24 [15200116.001]
  • [Cites] Surg Neurol. 1989 Apr;31(4):295-9 [2928924.001]
  • [Cites] Neurosurgery. 2005 Jul;57(1 Suppl):59-68; discussion 59-68 [15987570.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):299-305 [3719522.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):143-7 [15696976.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):501-4 [3042721.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Laryngorhinootologie. 1991 Jun;70(6):284-8 [1872929.001]
  • [Cites] Am J Surg. 1960 Sep;100:486-9 [13716296.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):12-20 [12134902.001]
  • [Cites] J Neurosurg Sci. 1997 Sep;41(3):283-92 [9444582.001]
  • [Cites] Minim Invasive Neurosurg. 2001 Dec;44(4):211-7 [11830780.001]
  • (PMID = 16195869.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Wada K, Maruno M, Suzuki T, Kagawa N, Hashiba T, Fujimoto Y, Hashimoto N, Izumoto S, Yoshimine T: Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray. Neurol Res; 2005 Oct;27(7):747-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray.
  • BACKGROUND: Meningioma is the commonest brain tumor and many genetic abnormalities, such as the loss of chromosome 22q and the mutation of NF2, have been reported.
  • METHODS: These classical abnormalities were detected using Southern blot, PCR, fluorescence in situ hybridization and comparative genomic hybridization, but these methods examine only very limited regions or limited mapping resolution of the tumor genome.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197812.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Mittelbronn M, Schittenhelm J, Lemke D, Ritz R, Nägele T, Weller M, Meyermann R, Beschorner R: Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components. Neuropathology; 2007 Oct;27(5):463-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components.
  • Gangliogliomas are rare CNS neoplasms mostly occuring in young adults and are usually assigned to WHO grade I.
  • The few cases of WHO grade IV gangliogliomas were either primarily malignant glio-neuronal tumors or underwent malignant progression from other WHO grades after radiotherapy.
  • Herein, we present the case of a now 47-year-old female patient presenting with a benign ganglioglioma and showing a tumor recurrence 2 years later with an anaplastic ganglioglioma, assigned to WHO grade IV, with malignant transformation in both glial and neuronal components.
  • The presented case is the first reported low-grade ganglioglioma rapidly progressing to a WHO grade IV glio-neuronal tumor not being associated with radiotherapy and showing malignant transformation in both astroglial and neuronal tumor cell components.
  • [MeSH-major] Astrocytes / pathology. Brain Neoplasms / pathology. Ganglioglioma / pathology. Neurons / pathology

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018481.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


25. Uzüm N, Ataoğlu GA: Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification. Tumori; 2008 May-Jun;94(3):389-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: Meningiomas are classified following the WHO system of 2000 into three grades, benign (grade I), atypical (grade II), and anaplastic (grade III).
  • We investigated the relation between tumor grade and Ki-67 and bcl-2.
  • The relationship between tumor grade and morphological parameters like pattern, mitotic index, cellularity, pleomorphism, nucleoli, small cell population with high nucleus/cytoplasmic ratio, necrosis and brain invasion was examined.
  • RESULTS: A correlation was found between all morphologic parameters except for brain invasion.
  • Ki-67 and bcl-2 expression was correlated with tumor grade, and the higher the tumor grade, the higher the Ki-67 and bcl-2 expression.
  • In conclusion, tumor grade appeared to be the most important parameter for a prognosis of meningiomas.
  • CONCLUSIONS: Ki-67 and bcl-2 expression might participate in carcinogenesis and when used with the grading system could provide additional benefit in assessing the biological behavior of the tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / analysis. Meningeal Neoplasms / chemistry. Meningeal Neoplasms / pathology. Meningioma / chemistry. Meningioma / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705408.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


26. Settin A, Ali N, Salem FK: Cytokine gene polymorphisms in Egyptian cases with brain tumors. Egypt J Immunol; 2008;15(2):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in Egyptian cases with brain tumors.
  • Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • To evaluate the association of polymorphisms of cytokine genes with brain tumors in Egyptian patients.
  • This study included 45 cases affected by brain tumors.
  • Their median age was 45, diagnosed as 24 benign cases and 21 malignant cases, and their sex included 20 males and 25 females.
  • Cases affected with benign brain tumors, showed a significant higher frequency of IL-10(-1082) A/A genotype (OR = 8.04, P < 0.001), IL-6(-174) C/C genotype (OR = 6.3, P < 0.001) and TNF-alpha(-308) A/A (OR = 4.7, P < 0.05) with a significant lower frequency of IL-10(-1082) G/A genotype (OR = 0.1, P < 0.001), IL-6(-174) G/C (OR = 0.2, P = 0.001) and TNF-alpha(-308) G/A was found significantly low among the same groups (OR = 0.2, P < 0.001) compared to controls.
  • The frequency of cytokines genotype and allele in malignant brain cases and controls.
  • Comparing studied genotype frequencies among benign and malignant brain tumor cases no significant difference was found in the frequencies of all studied genotypes and alleles with a non significant trend for the benign cases to have higher frequency of IL-10(-1082) AA genotype.
  • In conclusion, cytokine gene polymorphisms have a certain pattern among brain tumor cases and can be considered a genetic marker of potential value in counseling and management.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306684.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


27. Ghaemmaghami S, Ullman J, Ahn M, St Martin S, Prusiner SB: Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem; 2010 Apr 2;285(14):10415-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It remains to be established whether the formation of PrP(A) inhibits the formation of rPrP(Sc) by sequestering PrP(C) in the form of benign, insoluble aggregates.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Feb 6;279(5352):827-34 [9452375.001]
  • [Cites] J Biol Chem. 1992 Aug 15;267(23):16188-99 [1353761.001]
  • [Cites] J Virol. 1998 Nov;72(11):9413-8 [9765500.001]
  • [Cites] Nat Med. 1998 Oct;4(10):1157-65 [9771749.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3501-6 [15741275.001]
  • [Cites] J Gen Virol. 2005 Oct;86(Pt 10):2913-23 [16186247.001]
  • [Cites] Brain. 2006 Sep;129(Pt 9):2241-65 [16816391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19105-10 [17142317.001]
  • [Cites] Biochemistry. 2006 Dec 26;45(51):15710-7 [17176093.001]
  • [Cites] J Virol. 2007 Oct;81(20):11195-207 [17699584.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):17971-6 [17989223.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20914-9 [18096717.001]
  • [Cites] Ann Neurol. 2008 Jun;63(6):697-708 [18571782.001]
  • [Cites] J Neurochem. 2008 Oct;107(1):218-29 [18691383.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20417-22 [19915150.001]
  • [Cites] J Am Chem Soc. 2005 Oct 12;127(40):13802-3 [16201796.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14529-34 [10588739.001]
  • [Cites] J Virol. 2000 May;74(10):4894-7 [10775631.001]
  • [Cites] J Virol. 2001 Apr;75(7):3453-61 [11238871.001]
  • [Cites] N Engl J Med. 2001 May 17;344(20):1516-26 [11357156.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):3957-66 [11483499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9836-41 [11504948.001]
  • [Cites] Nature. 2001 Aug 16;412(6848):739-43 [11507642.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21140-8 [11912192.001]
  • [Cites] Biochemistry. 2002 Oct 22;41(42):12868-75 [12379130.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1785-8 [12386336.001]
  • [Cites] J Mol Biol. 2003 Feb 14;326(2):475-83 [12559915.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3416-21 [12626750.001]
  • [Cites] Br Med Bull. 2003;66:213-39 [14522861.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44826-31 [12944394.001]
  • [Cites] J Virol. 2004 Feb;78(4):2088-99 [14747574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8342-7 [15155909.001]
  • [Cites] Science. 2004 Jul 30;305(5684):673-6 [15286374.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41918-27 [15247213.001]
  • [Cites] Science. 1982 Apr 9;216(4542):136-44 [6801762.001]
  • [Cites] Science. 1982 Dec 24;218(4579):1309-11 [6815801.001]
  • [Cites] Biochemistry. 1983 Aug 2;22(16):3975-84 [6615812.001]
  • [Cites] Cell. 1983 Dec;35(2 Pt 1):349-58 [6418385.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2310-4 [3085093.001]
  • [Cites] Cell. 1986 Aug 1;46(3):417-28 [2873895.001]
  • [Cites] J Virol. 1987 Dec;61(12):3688-93 [2446004.001]
  • [Cites] J Virol. 1988 May;62(5):1558-64 [3282080.001]
  • [Cites] Science. 1990 Dec 14;250(4987):1587-90 [1980379.001]
  • [Cites] J Neurochem. 1992 Aug;59(2):768-71 [1352803.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9631-6 [9689132.001]
  • (PMID = 19955177.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / P01 AG002132; United States / NIA NIH HHS / AG / P01 AG010770; United States / NIA NIH HHS / AG / P01 AG021601; United States / NIA NIH HHS / AG / AG021601; United States / NIA NIH HHS / AG / AG02132; United States / NIA NIH HHS / AG / AG10770
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dendrimers; 0 / Nylons; 0 / PAMAM-G4; 0 / PrPC Proteins; 0 / PrPSc Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; EC 3.4.- / Endopeptidases
  • [Other-IDs] NLM/ PMC2856248
  •  go-up   go-down


28. Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M: Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol; 2006;45(7):796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staging procedures were thoracic and abdominal CT-scan, FDG-PET and CT or MRI of the brain in all patients.
  • Clinical target volume was the tumor as seen in lung windowing of CT and in FDG-PET.
  • We observed four (6%) local tumor recurrences, resulting in an actuarial local tumor control rate of 96%, 88% and 88% after 1, 2 and 3 year follow-up.
  • Nineteen patients died, with eight patients due to cancer (12%), two to local tumor progression alone.
  • Late effects were pneumonitis III degrees in 1%, rib fractures in 3%, and benign pleural effusion in 2 patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Dose Fractionation. Lung Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Fluorodeoxyglucose F18. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography / methods. Radiation Injuries / diagnosis. Radiation Injuries / epidemiology. Radiotherapy Dosage. Survival Analysis


29. Qian ZY, Wu YY, Huang Q, Zhai DZ, Zhu Q, Wang AD, Huo HM, Lan Q: [Expression of SV40Tag, Rb and IRS-1 in glioma detected by tissue microarray and their relation with tumorigenesis and progression of gliomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jun;30(6):432-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarrays were constructed containing 118 samples including human glioma and meningioma, experimental glioma, and normal human brain tissue.
  • RESULTS: The expressions of SV40Tag, Rb and IRS-1 were detected in gliomas and benign brain tumors.
  • Their positive expression rate in glioma was 65.9%, 64.6% and 48.8%, respectively, with a statistically non-significant difference between the malignant and benign brain tumors.
  • In the normal human brain tissue only the expression of Rb (77.8%, 7/9) and IRS-1 (22.2%, 2/9) were detected, but expression of SV40Tag could not be observed.
  • CONCLUSION: Our findings that no expression of SV40Tag was observed in normal human brain tissue indicates that expression of SV40Tag may play an important role in the pathogenesis of glioma.
  • [MeSH-major] Antigens, Polyomavirus Transforming / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Insulin Receptor Substrate Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Meningioma / metabolism. Meningioma / pathology. Mice. Middle Aged. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024517.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


30. Hulse RE, Swenson WG, Kunkler PE, White DM, Kraig RP: Monomeric IgG is neuroprotective via enhancing microglial recycling endocytosis and TNF-alpha. J Neurosci; 2008 Nov 19;28(47):12199-211
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In brain, monomeric immunoglobin G (IgG) is regarded as quiescent and only poised to initiate potentially injurious inflammatory reactions via immune complex formation associated with phagocytosis and tumor necrosis factor alpha (TNF-alpha) production in response to disease.
  • Using rat hippocampal slice and microglial cultures, here we show instead that physiological levels (i.e., 0.2-20 microg/ml) of monomeric IgG unassociated with disease triggered benign low-level proinflammatory signaling that was neuroprotective against CA1 area excitotoxicity and followed a U-shaped or hormetic dose-response.
  • Furthermore, like monomeric IgG these EP2 related effects took days to be effective, suggesting both were adaptive anabolic effects consistent with those seen from other long-term preconditioning stimuli requiring de novo protein synthesis.
  • The data provide the first evidence that brain monomeric IgG at physiological levels can have signaling function via enhanced recycling endocytosis/TNF-alpha production from microglia unassociated with disease and that these IgG-mediated changes may be a means by which paracrine signaling from neuronal activity influences microglia to evoke neuroprotection.
  • The data provide further support that low-level proinflammatory neural immune signaling unassociated with disease enhances brain function.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MINOCYCLINE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 1983 Oct;13(10):820-4 [6227488.001]
  • [Cites] J Cell Biol. 1984 Apr;98(4):1163-9 [6715403.001]
  • [Cites] J Cell Biol. 1985 Jun;100(6):1839-47 [3922993.001]
  • [Cites] J Exp Med. 1986 Apr 1;163(4):952-71 [3950548.001]
  • [Cites] Brain Res. 1988 May 24;449(1-2):395-8 [3395856.001]
  • [Cites] J Immunol. 1993 Apr 1;150(7):2659-67 [8454848.001]
  • [Cites] Neuron. 1993 Aug;11(2):371-86 [8352945.001]
  • [Cites] J Neurosci Res. 1993 Aug 1;35(5):567-76 [8377226.001]
  • [Cites] J Neurosci Res. 1994 Jul 1;38(4):365-75 [7932870.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Nov;57 Suppl:21-5 [7964846.001]
  • [Cites] J Neurosci. 1995 Nov;15(11):7702-11 [7472521.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Jan;17(1):26-43 [8978384.001]
  • [Cites] J Exp Med. 1997 Jan 20;185(2):305-16 [9016879.001]
  • [Cites] Stroke. 1997 Jun;28(6):1233-44 [9183357.001]
  • [Cites] Physiol Rev. 1997 Jul;77(3):759-803 [9234965.001]
  • [Cites] Ann Hematol. 1998 Jun;76(6):231-48 [9692811.001]
  • [Cites] Eur J Neurosci. 1998 Oct;10(10):3107-14 [9786205.001]
  • [Cites] J Neurochem. 1999 Feb;72(2):565-75 [9930728.001]
  • [Cites] J Immunol Methods. 1999 Feb 1;223(1):115-21 [10037239.001]
  • [Cites] J Cell Biol. 2004 Nov 8;167(3):531-43 [15534004.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Nov;24(11):1288-304 [15545925.001]
  • [Cites] Brain Res. 2005 Feb 9;1034(1-2):11-24 [15713255.001]
  • [Cites] J Neurosci. 2005 Apr 13;25(15):3952-61 [15829647.001]
  • [Cites] Brain Dev. 2005 Jun;27(4):275-8 [15862190.001]
  • [Cites] Immunity. 2005 May;22(5):539-50 [15894272.001]
  • [Cites] Peptides. 2005 Jun;26(6):985-1000 [15911067.001]
  • [Cites] Transfusion. 2005 Oct;45(10):1601-9 [16181211.001]
  • [Cites] Transfusion. 2005 Oct;45(10):1640-57 [16181216.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1492-5 [16282525.001]
  • [Cites] Immunity. 2006 Jan;24(1):19-28 [16413920.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):268-75 [16415867.001]
  • [Cites] Nature. 2006 Apr 20;440(7087):1054-9 [16547515.001]
  • [Cites] Glia. 2006 Jun;53(8):809-16 [16541436.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9685-90 [16769901.001]
  • [Cites] Exp Cell Res. 2006 Jul 15;312(12):2238-51 [16650848.001]
  • [Cites] J Cell Sci. 2006 Nov 1;119(Pt 21):4486-98 [17046995.001]
  • [Cites] Neurosci Lett. 2007 Apr 6;416(1):87-91 [17317005.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14104-9 [17715065.001]
  • [Cites] Neuron. 2008 Jun 12;58(5):673-80 [18549780.001]
  • [Cites] Crit Rev Toxicol. 2008;38(6):557-77 [18615310.001]
  • [Cites] J Biol Chem. 1994 Sep 30;269(39):24396-402 [7929100.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Jan;20(1):53-65 [10616793.001]
  • [Cites] Eur J Neurosci. 2000 Nov;12(11):3863-70 [11069581.001]
  • [Cites] Science. 2000 Dec 15;290(5499):2155-9 [11118151.001]
  • [Cites] J Neuroimmunol. 2001 Mar 1;114(1-2):168-72 [11240028.001]
  • [Cites] Glia. 2001 Apr 15;34(2):134-42 [11307162.001]
  • [Cites] J Neurosci. 2001 Apr 15;21(8):2580-8 [11306611.001]
  • [Cites] Science. 2002 Mar 22;295(5563):2282-5 [11910117.001]
  • [Cites] Immunity. 2002 Mar;16(3):379-89 [11911823.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1197-209 [12070131.001]
  • [Cites] Glia. 2002 Nov;40(2):133-9 [12379901.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):174-9 [12403778.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2003;43:175-97 [12195028.001]
  • [Cites] Trends Neurosci. 2003 May;26(5):248-54 [12744841.001]
  • [Cites] EMBO Rep. 2003 Oct;4(10):924-6 [14528258.001]
  • [Cites] J Neurosci. 2004 Jan 7;24(1):257-68 [14715958.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Feb;5(2):121-32 [15040445.001]
  • [Cites] J Neurosci Methods. 2004 Jun 15;136(1):87-98 [15126049.001]
  • [Cites] Prog Neurobiol. 2004 Feb;72(3):167-82 [15130708.001]
  • [Cites] Nat Rev Neurosci. 2004 Jul;5(7):521-31 [15208694.001]
  • [Cites] Glia. 2004 Oct;48(1):76-84 [15326617.001]
  • [Cites] Trends Endocrinol Metab. 2004 Aug;15(6):286-93 [15358282.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Aug;24(8):829-39 [15362713.001]
  • [Cites] Science. 2004 Sep 24;305(5692):1972-5 [15448273.001]
  • [Cites] Stroke. 2004 Nov;35(11):2576-81 [15375302.001]
  • [Cites] Adv Immunol. 1970;12:333-81 [4099771.001]
  • [Cites] Fed Proc. 1974 Sep;33(9):2075-8 [4424717.001]
  • [Cites] Lab Invest. 1980 Oct;43(4):342-51 [6160316.001]
  • (PMID = 19020014.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS019108-23; United States / NINDS NIH HHS / NS / R01 NS019108; United States / NINDS NIH HHS / NS / NS-19108; United States / NIGMS NIH HHS / GM / T32-GM07839; United States / NIGMS NIH HHS / GM / T32 GM007839; United States / NINDS NIH HHS / NS / NS019108-23
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ectodysplasins; 0 / Immunoglobulin G; 0 / Interleukin-1beta; 0 / Lysosomal-Associated Membrane Protein 1; 0 / Neuroprotective Agents; 0 / Neurotoxins; 0 / Tumor Necrosis Factor-alpha; 6384-92-5 / N-Methylaspartate; EC 3.6.1.- / rab GTP-Binding Proteins; EC 3.6.1.- / rab11 protein; EC 4.2.1.11 / Phosphopyruvate Hydratase; FYY3R43WGO / Minocycline; IY9XDZ35W2 / Glucose; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ NIHMS116423; NLM/ PMC2699401
  •  go-up   go-down


31. Jozwiak J, Grajkowska W, Kotulska K, Jozwiak S, Zalewski W, Zajaczkowska A, Roszkowski M, Slupianek A, Wlodarski P: Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med; 2007;9(2):117-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor formation in tuberous sclerosis depends on Erk activation.
  • Tuberous sclerosis (TS) is an autosomal dominant disease associated with the formation of usually benign tumors or hamartomas.
  • Here, we show for the first time that in all four brain lesions and one angiomyolipoma from TS patients both extracellular signal-regulated kinase (Erk) and p90 ribosomal S6 kinase 1 activation as well as Erk-dependent phosphorylation of p70 ribosomal S6 kinase 1 are markedly elevated whereas Akt, participating in the classical pathway of mammalian target of rapamycin activation is not always activated.
  • [MeSH-major] Brain Neoplasms / enzymology. Extracellular Signal-Regulated MAP Kinases / metabolism. Tuberous Sclerosis / pathology


32. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


33. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A: Molecular signatures define two main classes of meningiomas. Mol Cancer; 2007;6:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningiomas are common brain tumors that are classified into three World Health Organization grades (benign, atypical and malignant) and are molecularly ill-defined tumors.
  • While all benign meningiomas fall into the low-proliferative group and all malignant meningiomas fall into the high-proliferative group, atypical meningiomas distribute into either one of these groups.
  • We have identified genes that distinguish benign low-proliferative meningiomas from malignant high-proliferative meningiomas and have found that gain of cell-proliferation markers and loss of components of the transforming growth factor-beta signaling pathway were the major molecular mechanisms that distinguish these two groups.
  • CONCLUSION: Collectively, our data suggests that atypical meningiomas are not a molecularly distinct group but are similar to either benign or malignant meningiomas.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / classification. Meningeal Neoplasms / genetics. Meningioma / classification. Meningioma / genetics. Nucleic Acid Hybridization / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):445-54 [16772868.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2907-18 [15837741.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):360-8 [1328762.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] Genome Biol. 2003;4(1):R7 [12540299.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Genome Res. 2002 Feb;12(2):325-32 [11827952.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 17937814.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2173907
  •  go-up   go-down


34. Schaller BJ, Modo M, Buchfelder M: Molecular imaging of brain tumors: a bridge between clinical and molecular medicine? Mol Imaging Biol; 2007 Mar-Apr;9(2):60-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?
  • As the research on cellular changes has shed invaluable light on the pathophysiology and biochemistry of brain tumors, clinical and experimental use of molecular imaging methods is expanding and allows quantitative assessment.
  • Molecular imaging sets forth to probe the molecular abnormalities that are the basis of disease rather than to visualize the end effects of these molecular alterations and, therefore, provides different additional biochemical or molecular information about primary brain tumors compared to histological methods "classical" neuroradiological diagnostic studies.
  • Common clinical indications for molecular imaging contain primary brain tumor diagnosis and identification of the metabolically most active brain tumor reactions (differentiation of viable tumor tissue from necrosis), prediction of treatment response by measurement of tumor perfusion, or ischemia.
  • The interesting key question remains not only whether the magnitude of biochemical alterations demonstrated by molecular imaging reveals prognostic value with respect to survival, but also whether it identifies early disease and differentiates benign from malignant lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurons / diagnostic imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Animals. Cell- and Tissue-Based Therapy. Disease Models, Animal. Disease Progression. Humans. Molecular Probes. Neoplasm Staging. Radiography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2003 Jun;111(11):1620-9 [12782662.001]
  • [Cites] Nucl Med Commun. 2003 Nov;24(11):1149-54 [14569169.001]
  • [Cites] Acta Radiol. 1989 Mar-Apr;30(2):121-8 [2493795.001]
  • [Cites] J Nucl Med. 1993 Jan;34(1):12-7 [8418251.001]
  • [Cites] Ann Neurol. 2003 Oct;54(4):479-87 [14520660.001]
  • [Cites] Expert Opin Biol Ther. 2004 Feb;4(2):145-55 [14998774.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):309-35 [12926228.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8122-5 [14678964.001]
  • [Cites] J Comput Assist Tomogr. 1993 Sep-Oct;17 (5):681-7 [8370819.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1018-25 [15877226.001]
  • [Cites] Nucl Med Biol. 2004 Feb;31(2):179-89 [15013483.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9 [15711980.001]
  • [Cites] Expert Rev Neurother. 2006 May;6(5):723-30 [16734520.001]
  • [Cites] Neuroradiology. 1998 Feb;40(2):103-8 [9541920.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1862-7 [11912166.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1376-86 [12216107.001]
  • [Cites] J Neurooncol. 2004 May;68(1):1-9 [15174514.001]
  • [Cites] Acta Neurol Scand. 2005 Feb;111(2):75-83 [15644065.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):726-8 [2013813.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(2):103-11 [12132049.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):414-6 [15770001.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1530-8 [15378285.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1255-62 [14977823.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Blood. 2003 Jul 1;102(1):53-9 [12609836.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7571-4 [14633668.001]
  • [Cites] Hum Gene Ther. 2003 Feb 10;14(3):277-97 [12639307.001]
  • [Cites] Radiology. 2001 May;219(2):316-33 [11323453.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):491-5 [11228541.001]
  • [Cites] J Neurooncol. 1992 Feb;12 (2):159-65 [1560262.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Dev Neurosci. 2004 Mar-Aug;26(2-4):118-30 [15711055.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(1):1-15 [10664370.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Acta Radiol Suppl. 1986;369:157-60 [2980438.001]
  • [Cites] J Neurochem. 1977 May;28(5):897-916 [864466.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):498-507 [16235683.001]
  • [Cites] J Comput Assist Tomogr. 1992 Jan-Feb;16(1):62-8 [1729308.001]
  • [Cites] Chest. 2003 Aug;124(2):608-13 [12907550.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):994-1002; discussion 1002 [8084410.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19745-51 [10391916.001]
  • [Cites] Neurology. 1982 Dec;32(12 ):1323-9 [6983044.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Lancet. 2001 Sep 1;358(9283):727-9 [11551583.001]
  • [Cites] NeuroRx. 2005 Apr;2(2):333-47 [15897954.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):64-74 [16111573.001]
  • [Cites] Radiology. 1995 Oct;197(1):221-6 [7568827.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Acta Otolaryngol. 1997 Jul;117(4):482-9 [9288200.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):509-61 [8392523.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):393-403 [16513607.001]
  • [Cites] J Nucl Med. 2005 Mar;46(3):450-4 [15750158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] NMR Biomed. 2003 Apr;16(2):67-76 [12730947.001]
  • [Cites] Eur J Nucl Med. 2001 Dec;28(12 ):1851-72 [11734927.001]
  • [Cites] Invest Radiol. 1987 May;22(5):360-71 [3496318.001]
  • [Cites] Mol Imaging Biol. 2004 Jul-Aug;6(4):239-69 [15262239.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):207-15 [15332323.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] Mol Imaging Biol. 2004 May-Jun;6(3):139-48 [15193248.001]
  • [Cites] Eur J Nucl Med. 1997 Sep;24(9):1149-55 [9283109.001]
  • [Cites] Magn Reson Med. 2004 May;51(5):893-9 [15122670.001]
  • [Cites] J Nucl Med. 2001 Mar;42(3):467-75 [11337525.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] J Nucl Med. 2000 Apr;41(4):661-81 [10768568.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6101-8 [15342393.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):789-803; discussion 803-4 [9092853.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12 ):1962-9 [14660722.001]
  • [Cites] Nat Biotechnol. 2003 Apr;21(4):405-13 [12652311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9300-5 [11481488.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):157-63 [11206011.001]
  • [Cites] Q J Nucl Med. 1995 Sep;39(3):243-9 [7552947.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):1948-58 [16330557.001]
  • [Cites] J Neurosurg. 1999 Nov;91(5):797-803 [10541237.001]
  • [Cites] Eur J Nucl Med. 1997 Apr;24(4):428-34 [9096095.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:139-43 [12401680.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2572-9 [15059914.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1459-62 [9293808.001]
  • [Cites] J Neurooncol. 1999 Jul;43(3):231-6 [10563428.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):505-11; discussion 505-11 [16145529.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Leukemia. 2002 Feb;16(2):260-7 [11840293.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51 [15014901.001]
  • [Cites] J Cereb Blood Flow Metab. 1984 Jun;4(2):212-23 [6609929.001]
  • [Cites] Blood. 2005 Jan 1;105(1):420-5 [15331444.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1062-6 [6415134.001]
  • [Cites] J Neuroimaging. 2003 Jul;13(3):269-71 [12889176.001]
  • [Cites] J Nucl Med. 1994 Jul;35(7):1162-6 [8014676.001]
  • [Cites] Nat Med. 2000 Apr;6(4):447-50 [10742153.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):28-33 [8355844.001]
  • [Cites] J Cereb Blood Flow Metab. 1991 May;11(3):485-91 [2016357.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jan;150(1):189-97 [3257119.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Magn Reson Imaging. 2004 Apr;19(4):389-96 [15065161.001]
  • [Cites] Exp Cell Res. 2005 Jun 10;306(2):323-9 [15925587.001]
  • [Cites] Radiology. 1993 Jan;186(1):45-53 [8380108.001]
  • [Cites] J Nucl Med. 1999 Mar;40(3):381-6 [10086699.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):720-8 [2586726.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1257-60 [15502845.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5347-54 [15289341.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] J Nucl Med. 1991 Jul;32(7):1338-46 [1906093.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1369-74 [9293789.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2983-95 [11306477.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Trends Neurosci. 2005 Mar;28(3):120-6 [15749164.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):265-72 [11134222.001]
  • [Cites] Clin Nucl Med. 1996 Sep;21(9):720-5 [8879874.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] J Neurosurg. 2003 May;98 (5):1056-64 [12744366.001]
  • [Cites] Nervenarzt. 2003 Dec;74(12):1134-6 [14647916.001]
  • [Cites] Neurobiol Dis. 2004 Apr;15(3):437-48 [15056451.001]
  • [Cites] Radiographics. 1992 Mar;12 (2):269-79 [1561416.001]
  • [Cites] Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):129-35 [9711745.001]
  • [Cites] Eur J Nucl Med. 1996 May;23 (5):583-6 [8698067.001]
  • [Cites] Pediatr Neurosurg. 1997 Mar;26(3):144-56 [9419031.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1939-45 [15534066.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2836-42 [7954245.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1074-8 [3261622.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):816-22 [2987440.001]
  • (PMID = 17203238.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes
  • [Number-of-references] 135
  •  go-up   go-down


35. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I: iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res; 2008 Mar;7(3):897-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential expression of brain creatine kinase (CKBB), soluble catechol-O-methyltransferase (S-COMT), tumor rejection antigen (gp96), and glucose regulated protein, 78 kDa (grp78), was confirmed by Western blotting or independent 2D-PAGE analysis.
  • The clinical relevance of gp96 was assessed by immunohistochemistry using prostate tissues from benign ( n = 95), malignant ( n = 66), and metastatic cases ( n = 3).
  • Benign epithelium showed absent/weak gp96 expression in the basal cells, in contrast to the moderate/strong expression seen in malignant epithelium.
  • Furthermore, there was a statistically significant difference in the intensity of gp96 expression between benign and malignant cases ( p < 0.0005, Mann-Whitney U).
  • [MeSH-major] Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism. Proteomics
  • [MeSH-minor] Cell Line, Tumor. Chromatography, Liquid. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Male. Reproducibility of Results. Spectrometry, Mass, Electrospray Ionization / methods


36. Bodack MI: Ptosis and cranial nerve IV palsy reveal juvenile myasthenia gravis. Optometry; 2009 Jul;80(7):342-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both cases, these conditions can be benign and require no further workup.
  • If a patient presents with multiple neurologic signs, a sudden onset eye turn, or ptosis, the patient must undergo a workup to rule out a pathologic etiology, specifically a brain tumor.
  • If the results of the neuroimaging are normal, and the findings are variable, myasthenia gravis should be considered, and additional testing should be ordered to assist in the diagnosis.
  • Diagnosis of myasthenia gravis was made based on clinical presentation and response to ice pack testing.
  • CONCLUSIONS: Although rare, myasthenia should be considered a diagnosis in children who present with variable ptosis or strabismus.
  • [MeSH-major] Blepharoptosis / etiology. Myasthenia Gravis / complications. Myasthenia Gravis / diagnosis. Strabismus / etiology. Trochlear Nerve Diseases / etiology
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neurology. Optometry. Referral and Consultation

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • Genetic Alliance. consumer health - Ptosis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Optometry. 2009 Sep;80(9):466
  • (PMID = 19545846.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Benedict WJ Jr, Brown HG, Sivarajan G, Prabhu VC: Intraventricular schwannoma in a 15-year-old adolescent: a case report. Childs Nerv Syst; 2008 Apr;24(4):529-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Schwannomas are benign tumors that originate from the myelin-forming Schwann cells of peripheral nerves or at the Obersteiner-Redlich zone of the vestibular division of the eighth cranial nerve.
  • DISCUSSION: This case report illustrates a right occipital horn schwannoma in a 15-year-old adolescent boy who was successfully treated with surgical resection and discusses the possible origins of the tumor in this unique location.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Neurilemmoma / diagnosis. Neurilemmoma / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):561-2 [15799168.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(4):473-6; discussion 477 [10883347.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Feb;46(1):50-3 [12640585.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):777-81 [2213169.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):37-43 [8455061.001]
  • [Cites] J Neurosurg. 1995 Jan;82(1):121-4 [7815115.001]
  • [Cites] Childs Nerv Syst. 1988 Dec;4(6):373-5 [3073004.001]
  • [Cites] Brain Pathol. 2006 Jan;16(1):87-8, 93 [16612987.001]
  • [Cites] Pediatr Pathol Lab Med. 1997 Jan-Feb;17(1):1-25 [9050057.001]
  • (PMID = 18175126.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


38. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM: Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun; 2008 Aug;22(6):890-900
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adaptive immune response of ovarian cancer patients has been linked to survival, and is known to be impaired in the tumor microenvironment.
  • Thirty-seven patients with epithelial ovarian cancer and 14 patients with benign ovarian neoplasms completed psychosocial questionnaires pre-surgery.
  • Lymphocytes from peripheral blood, tumor, and ascites (fluid around the tumor), were obtained on the day of surgery.
  • Expression of the Type-1 cytokine interferon-gamma (IFN gamma), and the Type-2 cytokine interleukin-4 (IL-4) by T-helper (CD4(+)) and T-cytotoxic (CD8(+)) cells was measured under autologous tumor-stimulated, polyclonally-stimulated, or unstimulated conditions.
  • Among cancer patients, marked elevations in unstimulated and tumor-stimulated Type-2 responses were seen, particularly in ascites and tumor-infiltrating lymphocytes (P values<0.01).
  • Although effects of polyclonal stimulation should be generalized with caution to the in vivo immune response, findings suggest that depressed and anxious mood are associated with greater impairment of adaptive immunity in peripheral blood and in the tumor microenvironment among ovarian cancer patients.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1327-35 [9815928.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):83-107 [9450372.001]
  • [Cites] J Formos Med Assoc. 1999 Jan;98(1):24-30 [10063270.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6671-80 [10352285.001]
  • [Cites] Cancer Immunol Immunother. 1999 May-Jun;48(2-3):147-52 [10414469.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):1923-8 [10438927.001]
  • [Cites] Adv Exp Med Biol. 1999;461:1-24 [10442164.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2492-9 [10452985.001]
  • [Cites] J Exp Med. 1999 Sep 6;190(5):617-27 [10477547.001]
  • [Cites] J Psychosom Res. 2004 Oct;57(4):353-8 [15518669.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1598-605 [15547530.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):590-6 [15699022.001]
  • [Cites] Psychosom Med. 2005 Jul-Aug;67(4):638-42 [16046380.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):571-80 [16397274.001]
  • [Cites] Brain Behav Immun. 2007 Feb;21(2):185-94 [16908118.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):374-83 [17360153.001]
  • [Cites] Springer Semin Immunopathol. 1999;21(3):231-48 [10666771.001]
  • [Cites] J Consult Clin Psychol. 2000 Feb;68(1):31-45 [10710838.001]
  • [Cites] Ann Behav Med. 2000 Winter;22(1):29-37 [10892526.001]
  • [Cites] Nat Med. 2001 Feb;7(2):206-14 [11175852.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:94-105 [11268424.001]
  • [Cites] Surgery. 2001 Jun;129(6):749-56 [11391375.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):654-8 [11402277.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Aug;56(8):M477-82 [11487599.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6497-502 [11714817.001]
  • [Cites] Brain Behav Immun. 2002 Feb;16(1):1-16 [11846437.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):387-93 [12566422.001]
  • [Cites] Brain Behav Immun. 2003 Apr;17(2):69-85 [12676570.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6784-90 [14583474.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):64-75 [14764031.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):1-8 [14987957.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5467-77 [15100288.001]
  • [Cites] Psychol Bull. 2004 Jul;130(4):601-30 [15250815.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1024:138-46 [15265778.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3570-80 [15337807.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):617-25 [15465465.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1133-9 [7193084.001]
  • [Cites] J Pers Assess. 1983 Jun;47(3):305-6 [6886962.001]
  • [Cites] Obstet Gynecol. 1984 Nov;64(5):708-14 [6493663.001]
  • [Cites] Mol Pharmacol. 1987 Apr;31(4):377-84 [3033466.001]
  • [Cites] J Consult Clin Psychol. 1989 Dec;57(6):683-91 [2600238.001]
  • [Cites] J Immunol. 1990 Mar 15;144(6):2211-5 [1968925.001]
  • [Cites] J Immunol. 1991 Mar 1;146(5):1700-7 [1704404.001]
  • [Cites] Immunol Lett. 1991 Sep;30(1):141-2 [1683651.001]
  • [Cites] JAMA. 1992 Mar 4;267(9):1244-52 [1538563.001]
  • [Cites] Gynecol Obstet Invest. 1993;35(2):118-20 [8383627.001]
  • [Cites] Brain Behav Immun. 1993 Jun;7(2):154-63 [8394164.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):429-37 [8123759.001]
  • [Cites] Proc Assoc Am Physicians. 1996 Sep;108(5):374-81 [8902882.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):276-84 [8903466.001]
  • [Cites] J Allergy Clin Immunol. 1996 Dec;98(6 Pt 2):S161-73 [8977524.001]
  • [Cites] Cell Immunol. 1997 Feb 1;175(2):150-6 [9023420.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):30-6 [9428780.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • (PMID = 18276105.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104825-01; United States / NCI NIH HHS / CA / R21CA88293; United States / NCI NIH HHS / CA / R01CA104825; United States / NCI NIH HHS / CA / R01 CA104825; United States / NCI NIH HHS / CA / R21 CA088293-01; United States / NCI NIH HHS / CA / CA088293-01; United States / NCI NIH HHS / CA / R21 CA088293; United States / NCI NIH HHS / CA / R01 CA104825-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon Type I; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ NIHMS59847; NLM/ PMC2605940
  •  go-up   go-down


39. Sumiyoshi T, Sumiyoshi C, Nohara S, Hagino H, Hasegawa S, Kuwayama N, Endo S, Kurachi M: Verbal memory deficits in a preadolescent case of lesions of the left parahippocampal gyrus associated with a benign tumor. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun;30(4):733-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Verbal memory deficits in a preadolescent case of lesions of the left parahippocampal gyrus associated with a benign tumor.
  • Neuropsychological examinations soon after the removal of the tumor showed selective deficits in semantic memory function, as evaluated by the Category Fluency Task and the Wechsler Memory Scale-Revised, while visual memory, attention, and IQ were not affected.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hemangioma, Cavernous / physiopathology. Memory Disorders / pathology. Parahippocampal Gyrus / pathology. Verbal Learning / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442196.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY: A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg; 2010 May;112(5):925-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
  • The goal of this study was to identify clinical characteristics associated with the recurrence of benign meningiomas and their acceleration to atypical and malignant histological types.
  • Consequently, patients with Grade I non-skull base cranial meningiomas had better 5-year recurrence-free survival (69%) than patients with Grade I skull base meningiomas (56%) or Grade II or III tumors at any site (50%; p = 0.005).
  • Unexpectedly, patients with non-skull base tumors who experienced a recurrence (8 of 22 [36%]) were more likely than patients with skull base tumors (1 of 19 [5%]) to have a higher grade tumor at recurrence (p = 0.024).
  • Furthermore, the median MIB-1 labeling index of Grade I non-skull base cranial meningiomas (2.60%) was significantly higher than that of Grade I skull base tumors (1.35%; p = 0.016).
  • CONCLUSIONS: Cranial meningiomas that occur outside of the skull base are more likely to have a higher MIB-1 labeling index and recur with a higher grade than those within the skull base, suggesting that non-skull base cranial tumors may have a more aggressive biology than skull base tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local. Skull Base Neoplasms / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799498.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Lauretti L, Fernandez E, Pallini R, Massimi L, Albanese A, Denaro L, Maira G: Long survival in an untreated solitary choroid plexus metastasis from renal cell carcinoma: case report and review of the literature. J Neurooncol; 2005 Jan;71(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases from renal cell carcinoma (RCC) are rare.
  • For several years, such metastasis was interpreted as a benign intraventricular tumor and was not treated.
  • Four years after the initial neuroradiological evidence, because of the appearance of symptoms, the brain metastasis was excised.
  • We think that this unusual biological behaviour of the tumor determined the late inset of the neurological symptoms, despite the location at the choroid plexus that usually leads to an early obstructive hydrocephalus.
  • [MeSH-major] Carcinoma, Renal Cell / physiopathology. Carcinoma, Renal Cell / secondary. Choroid Plexus Neoplasms / physiopathology. Choroid Plexus Neoplasms / secondary. Kidney Neoplasms / pathology
  • [MeSH-minor] Aged. Cerebral Angiography. Female. Humans. Magnetic Resonance Imaging. Survival Analysis

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Med. 1996 Mar-Apr;14(2):71-6 [8776768.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990;30(11 Spec No):869-73 [1709467.001]
  • [Cites] J Clin Oncol. 1984 Mar;2(3):169-73 [6699668.001]
  • [Cites] Eur Urol. 1999 Sep;36(3):230-5 [10450008.001]
  • [Cites] Neurol Med Chir (Tokyo). 1994 Mar;34(3):183-6 [7516049.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):257-8 [11796778.001]
  • [Cites] Arch Neurol. 1978 Nov;35(11):754-6 [718475.001]
  • [Cites] South Med J. 1998 Dec;91(12 ):1159-62 [9853731.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1971 Feb;111(2):334-6 [5541678.001]
  • [Cites] J Urol. 1978 Aug;120(2):148-52 [78992.001]
  • [Cites] Neurol Med Chir (Tokyo). 1991 Mar;31(3):152-5 [1715049.001]
  • [Cites] Zentralbl Allg Pathol. 1982;126(1-2):64-73 [7090603.001]
  • [Cites] W V Med J. 1996 Jan-Feb;92(1):26-7 [8599244.001]
  • [Cites] Radiology. 1980 Jul;136(1):124 [6247741.001]
  • [Cites] Surg Clin North Am. 1967 Jun;47(3):737-42 [6022983.001]
  • [Cites] No Shinkei Geka. 1992 Apr;20(4):469-74 [1570073.001]
  • [Cites] Neuroradiology. 1983;25(1):11-22 [6856076.001]
  • [Cites] J Neurosurg. 2000 May;92(5):760-5 [10794288.001]
  • [Cites] Urology. 1996 Feb;47(2):187-93 [8607231.001]
  • [Cites] J Surg Oncol. 1974;6(2):97-107 [4822902.001]
  • [Cites] Klin Padiatr. 1987 Nov-Dec;199(6):424-8 [3431021.001]
  • [Cites] J Comput Assist Tomogr. 1986 May-Jun;10 (3):537-40 [3700764.001]
  • [Cites] Cancer. 1971 Nov;28(5):1165-77 [5125665.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1487-91 [7272969.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):47-52 [8699225.001]
  • (PMID = 15690132.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


42. Goutagny S, Kalamarides M: Meningiomas and neurofibromatosis. J Neurooncol; 2010 Sep;99(3):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 2 (NF2) is a rare genetic disorder predisposing to multiple benign tumors of the nervous system.
  • Whether meningiomas are part of the schwannomatosis tumor phenotype or not remains debated.
  • Thus, knowledge of tumor behavior is essential in slow growing tumors like meningiomas, to balance the risk of treatment against the natural history of the disease, and to evaluate the efficiency of alternative therapeutics (radiation therapy or new drugs).
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neurofibromatoses / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5032-5039 [19671848.001]
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):208-13 [18687535.001]
  • [Cites] Neuropediatrics. 2005 Feb;36(1):21-34 [15776319.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):610-4 [9322850.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Neurology. 1993 Oct;43(10):2096-8 [8413972.001]
  • [Cites] J Med Genet. 2003 Feb;40(2):109-14 [12566519.001]
  • [Cites] J Med Genet. 2002 May;39(5):315-22 [12011146.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] J Pathol. 2001 Jul;194(3):367-72 [11439370.001]
  • [Cites] Neurogenetics. 2010 Feb;11(1):73-80 [19582488.001]
  • [Cites] BMC Med Genomics. 2009 Jul 09;2:42 [19589153.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] Acta Neurochir (Wien). 1995;137(3-4):174-81 [8789658.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] J Med Genet. 2005 Jan;42(1):45-8 [15635074.001]
  • [Cites] Arch Ophthalmol. 2007 Mar;125(3):389-94 [17353411.001]
  • [Cites] Neurosurgery. 2007 Mar;60(3):460-8; discussion 468-70 [17327790.001]
  • [Cites] Am J Med Genet A. 2010 Feb;152A(2):327-32 [20082463.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] Rev Neurol (Paris). 2005 Mar;161(3):275-83 [15800448.001]
  • [Cites] J Med Genet. 2010 Aug;47(8):567-8 [20472658.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):504-12 [10850863.001]
  • [Cites] J Neurosurg. 2009 Sep;111(3):458-63 [19199473.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6 Suppl):489-95 [16383246.001]
  • [Cites] Clin Genet. 2007 Apr;71(4):354-8 [17470137.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1068-1077 [16765675.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):562-9 [9488313.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Arch Dis Child. 1999 Dec;81(6):496-9 [10569966.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Neurology. 1996 Apr;46(4):1072-9 [8780094.001]
  • [Cites] Am J Hum Genet. 1998 Sep;63(3):727-36 [9718334.001]
  • [Cites] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):705-9 [7674021.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):480-3 [12959433.001]
  • [Cites] Br J Ophthalmol. 1992 May;76(5):310-2 [1390517.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Clin Genet. 2008 Oct;74(4):358-66 [18647326.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):447-53 [8113857.001]
  • (PMID = 20714782.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


43. Xu Y, Jing Y, Ma S, Ma F, Wang Y, Ma W, Li Q: Primary angioleiomyoma in the sellar region: a case report and literature review. Clin Neuropathol; 2010 Jan-Feb;29(1):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Angioleiomyoma (vascular leiomyomas, angiomyoma) is a rare, benign soft tissue tumor which consists of a mixture of well-differentiated smooth muscle cells and thick-walled vessels.
  • Gross total resection of the tumor was then performed.
  • The pertinent literature regarding the features of this tumor was reviewed and discussed.
  • CONCLUSIONS: Intracranial angioleiomyoma is a benign soft tissue tumor with excellent prognosis.
  • Early diagnosis of this tumor is difficult.
  • [MeSH-major] Angiomyoma / pathology. Brain / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adrenocorticotropic Hormone / metabolism. Early Diagnosis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040329.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 14
  •  go-up   go-down


44. Bricaire C, Plu-Bureau G: [Difficult contraceptions]. Rev Prat; 2008 Jan 15;58(1):55-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, we will address the issues faced in patients with neurological diseases (epilepsy, brain tumor, migraine, prolactin-secreting adenoma), vascular diseases (venous thrombosis, biological thrombophilia, arterial diseases), metabolic disorders (obesity, dyslipemias, diabetes), uterine diseases (fibromas, endometriosis), renal failure, benign and malignant breast diseases as well as in HIV-positive women.

  • MedlinePlus Health Information. consumer health - Birth Control.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326363.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 22
  •  go-up   go-down


45. Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL: Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther; 2009 Dec;16(12):1477-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In benign prostate tissues, G207 and G47Delta titers were notably reduced, whereas strain F titers were maintained at similar levels compared with prostate cancer specimens.

  • Genetic Alliance. consumer health - Prostate cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2000 Apr;74(8):3832-41 [10729157.001]
  • [Cites] Nat Rev Microbiol. 2008 Jul;6(7):529-40 [18552863.001]
  • [Cites] Urology. 2000 Jul;56(1):160-6 [10869659.001]
  • [Cites] Rev Med Virol. 2000 Sep-Oct;10(5):305-19 [11015742.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5714-22 [11059765.001]
  • [Cites] Hum Gene Ther. 2000 Dec 10;11(18):2465-72 [11119418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401 [11353831.001]
  • [Cites] Hum Gene Ther. 2001 May 20;12(8):999-1010 [11387063.001]
  • [Cites] Urology. 2001 Oct;58(4):619-24 [11597556.001]
  • [Cites] Neoplasia. 2001 Sep-Oct;3(5):451-6 [11687957.001]
  • [Cites] Dev Biol. 2004 Mar 15;267(2):387-98 [15013801.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5199-207 [7693334.001]
  • [Cites] Nat Med. 1995 Sep;1(9):938-43 [7585221.001]
  • [Cites] J Clin Invest. 1997 Feb 15;99(4):618-27 [9045863.001]
  • [Cites] J Virol. 1997 Aug;71(8):6049-54 [9223497.001]
  • [Cites] J Virol. 1998 Sep;72(9):7005-11 [9696792.001]
  • [Cites] J Virol. 1998 Sep;72(9):7064-74 [9696799.001]
  • [Cites] Hum Gene Ther. 1999 Sep 1;10(13):2237-43 [10498254.001]
  • [Cites] Gene Ther. 1999 Oct;6(10):1751-8 [10516725.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1532-40 [15735042.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1257-68 [15824085.001]
  • [Cites] Cancer Gene Ther. 2006 Mar;13(3):253-65 [16179929.001]
  • [Cites] Arch Pathol Lab Med. 2006 Aug;130(8):1193-5 [16879022.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):103-13 [17164781.001]
  • [Cites] J Virol. 2007 Apr;81(7):3455-64 [17229694.001]
  • [Cites] J Virol. 2008 Jan;82(2):999-1010 [17977977.001]
  • [Cites] FASEB J. 2008 Jun;22(6):1839-48 [18234972.001]
  • [Cites] Gene Ther. 2000 May;7(10):867-74 [10845725.001]
  • (PMID = 19693098.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102139-06A1; United States / NCI NIH HHS / CA / R01 CA102139; United States / NCI NIH HHS / CA / R01 CA102139-06A1
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS180783; NLM/ PMC2836587
  •  go-up   go-down


46. Maes L, Kalala JP, Cornelissen M, de Ridder L: Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif; 2007 Feb;40(1):14-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By verifying the proliferation capacity, human telomerase reverse transcriptase (hTERT) expression and in vitro invasion, in a group of highly malignant glioblastomas, benign meningiomas and astrocytomas, at the initial stage of progression, we have analysed putative progression in vitro for proliferation and telomerase expression.
  • MATERIALS AND METHODS: The relative proliferation status (visualized with Ki-67 antibodies) and presence of hTERT protein was analysed in 27 intracranial tumours (6 astrocytomas, 8 glioblastomas and 13 meningiomas) by immunohistochemistry on paraffin-embedded biopsy tissue, as well as on primary tumour-derived cell cultures.
  • The group of benign meningiomas had a labelling index of 2.2 (SD = 2.7).
  • The group of benign meningiomas had a labelling index of 12.4 (SD = 19.2) for hTERT.
  • No difference was seen between the group of invasive and non-invasive tumour-derived cell cultures for the histopathological markers Ki-67 and hTERT (P > 0.05) in vitro.
  • CONCLUSIONS: The elevated expression of hTERT and Ki-67 in vitro provides a potential prognostic tool for early detection of the progression of brain tumours.
  • As tumour cells require telomerase for continued proliferation, the expression of hTERT may mark immortality, leading to indefinite life span.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Proliferation. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Telomerase / analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227292.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


47. Zhou LF, Mao Y, Zhang R: Surgical treatment of dumbbell-shaped neurinomas: report of an experience with 57 cases in a single hospital. Surg Neurol; 2007 Dec;68(6):594-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Dumbbell-shaped trigeminal neurinomas are rare benign tumors with a controversy regarding their treatment and surgical approaches.
  • METHODS: One hundred thirty-seven patients with trigeminal neurinomas, accounting for 0.6% of all intracranial tumors and 3.8% of intracranial neurinomas, were screened out from the data bank on brain tumors in Hua Shan Hospital (Shanghai, China) from 1978 to 2003.
  • After the tumor in the middle cranial fossa was resected, the tumor in the posterior fossa was resected via a suboccipital approach in the early group and through enlarged porus trigeminus without resection of the petrous apex in the latter group.
  • RESULTS: There were 12 patients in the early group and 45 patients (including 6 patients with recurrent tumors) in the latter group.
  • Tumor size measured on MRI and/or CT were 30 to 40 mm in 4 (33%) cases from the early group and 14 (31%) cases from the latter group, 41 to 50 mm in 8 (67%) cases from the early group and 25 (56%) cases from the latter group, and more than 50 mm in 6 (13%) cases from the latter group.
  • There were 3 patients in the latter group with a tumor extending into the infratemporal fossa and pterygopalatine fossa.
  • Total tumor resection was achieved in 42% (5/12) of the early group and 87% (39/45) of the latter group (chi(2) = 10.897, P < .001); incomplete tumor removal was done in 58% (7/12) of the early group and 13% (6/45) of the latter group.
  • Recurrent tumors occurred in 3 patients from the early group and were reoperated on.
  • One patient with a recurrent tumor from the latter group underwent radiosurgery 5 years after the operation.
  • It is not necessary to resect the petrous apex for removal of the tumor in the posterior fossa.
  • Radiosurgery can be used for the residual or recurrent tumors.
  • [MeSH-major] Cranial Nerve Neoplasms / pathology. Cranial Nerve Neoplasms / surgery. Neurilemmoma / pathology. Neurilemmoma / surgery. Trigeminal Nerve / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053854.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Pui MH, Wang Y: Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children. Clin Imaging; 2005 May-Jun;29(3):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion and magnetization transfer MRI of brain infarct, infection, and tumor in children.
  • The purpose of this study was to determine the efficacy of diffusion-weighted imaging (DWI) and magnetization transfer imaging (MTI) in the differential diagnosis of brain infarct, infection, hamartoma, and tumor in 106 children.
  • There was an inverse relationship between ADC and MTR in subacute/chronic infarct, infection, hamartoma, arachnoid cyst, and tumor relative to normal brain parenchyma.
  • DWI and MTI had a complementary role in the differential diagnosis of acute infarct from infection with lower MTR, from hamartoma with higher ADC, and from low-grade gliomas and benign tumors that had higher ADCs and lower MTRs.
  • ADCs increased and MTRs decreased with the duration of infarct and lower tumor grade.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Central Nervous System Infections / diagnosis. Cerebral Infarction / diagnosis. Diffusion Magnetic Resonance Imaging. Image Processing, Computer-Assisted
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855060.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Jacquin A, Béjot Y, Hervieu M, Biotti D, Caillier M, Ricolfi FC, Moreau T, Giroud M: [Rupture of intracranial dermoid cyst with disseminated lipid droplets]. Rev Neurol (Paris); 2010 Apr;166(4):451-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Dissémination sous-arachnoïdienne de gouttelettes lipidiques par rupture d'un kyste dermoïde intracérébral.
  • INTRODUCTION: Dermoid cysts are rare slow-growing benign tumors of the central nervous system generally diagnosed in the third to fifth decade.
  • CASE REPORTS: We report two cases of ruptured intracranial dermoid tumor with non-specific clinical presentations.
  • The first rupture was asymptomatic and discovered on brain magnetic resonance imaging (MRI) performed for other purposes.
  • The second case was identified on brain imaging performed because of daily headache.
  • Monitoring with brain MRI can be sufficient if the rupture has no severe clinical impact.
  • [MeSH-major] Brain Neoplasms / pathology. Dermoid Cyst / pathology. Lipid Metabolism / physiology
  • [MeSH-minor] Adult. Brain / pathology. Headache / etiology. Humans. Magnetic Resonance Imaging. Male. Rupture. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19846186.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


50. Sampetrean O, Maehara T, Arai N, Nemoto T: Rapidly growing dysembryoplastic neuroepithelial tumor: case report. Neurosurgery; 2006 Dec;59(6):E1337-8; discussion E1338
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing dysembryoplastic neuroepithelial tumor: case report.
  • OBJECTIVE: During the past 15 years, the concept of dysembryoplastic neuroepithelial tumors has continued to evolve.
  • We present an interesting case of dysembryoplastic neuroepithelial tumor that showed rapid growth during a short period of time.
  • INTERVENTION: A combined tumor removal and epileptogenic focus resection surgery was performed immediately.
  • In the pathological examination, the presence of the specific glioneuronal element with a Ki-67 labeling index of lower than 1%, as well as the glial component with a Ki-67 labeling index of 8%, led to a postoperative diagnosis of dysembryoplastic neuroepithelial tumor, complex form.
  • CONCLUSION: The lesion did not behave as a stable benign entity as it is generally accepted, and is, therefore, presented as an argument in favor of an early and complete resection.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasms, Neuroepithelial / pathology. Neoplasms, Neuroepithelial / surgery. Temporal Lobe / pathology. Temporal Lobe / surgery. Teratoma / pathology. Teratoma / surgery
  • [MeSH-minor] Child. Humans. Male. Seizures / diagnosis. Seizures / etiology


51. Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E: Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding? J Neurosurg; 2009 Sep;111(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.
  • Although unusual, malignant transformation with leptomeningeal seeding into the brain or spinal cord may occur years after the initial diagnosis.
  • The authors report a unique case of multifocal benign meningeal melanocytoma involving both cerebellopontine angles and the thoracic spinal cord, with associated diffuse leptomeningeal hyperpigmentation.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361258.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Uro-Coste E, Ssi-Yan-Kai G, Guilbeau-Frugier C, Boetto S, Bertozzi AI, Sevely A, Lolmede K, Delisle MB: Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation. J Neurooncol; 2010 May;98(1):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation.
  • Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are rare intracranial tumors that mostly occur in the first 2 years of life and involve superficial cerebral cortex.
  • Magnetic resonance imaging showed a temporal tumor with prepontine and interpeduncular extension, and two other distinct localizations in cisterna magna and left cerebellar hemisphere.
  • When the tumor is large, multilobular involvement is common, but multiple location of DIG is, on the contrary, very rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Brain / diagnostic imaging. Brain / pathology. Child, Preschool. Humans. Magnetic Resonance Imaging / methods. Male. Radiography. Tomography Scanners, X-Ray Computed


53. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


54. Chen CL, Shen CC, Wang J, Lu CH, Lee HT: Central neurocytoma: a clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg; 2008 Feb;110(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Central neurocytoma is a rare intraventricular brain tumor that affects young adults and presents with increased intracranial pressure secondary to obstructive hydrocephalus.
  • In this report, we describe the diagnosis and treatment of central neurocytoma in a series of patients at our institution.
  • PATIENTS AND METHODS: Our series of nine patients (M:F=2:7, mean age, 28.2 years) with ventricular tumors showed typical radiological, histologic and immunohistochemical features of central neurocytoma.
  • Most patients received craniotomy with removal of the tumor through transcallosal or transcortical approach.
  • CONCLUSION: Although central neurocytoma is generally a benign neoplasm, some variant forms of recurrence are also present.
  • Recurrent tumors are often local and the patients seem to recover well after a second resection followed by radiotherapy.
  • Histologic features such as tumor proliferation (MIB-1 labeling index), vascular proliferation, and synaptophysin expression are often prominent in the recurrent tumor.
  • We recommend that these histologic features be considered for tumor recurrence during treatment and follow-up of these patients.

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1):7-12 [17639866.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] Surg Neurol. 2001 Feb;55(2):74-8 [11301084.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):879-82 [11702880.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1365-7 [12015858.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):126-32 [12046730.001]
  • [Cites] Neurology. 2002 Oct 22;59(8):1268-70 [12391364.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):256-60 [12541233.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):255-9 [12675319.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):560-5 [14670681.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Acta Neuropathol. 1990;79(5):473-9 [2109481.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):231-8 [2086738.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):585-91 [1901927.001]
  • [Cites] Neuroradiology. 1991;33(2):143-8 [2046899.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):32-7 [1727166.001]
  • [Cites] Radiology. 1992 Mar;182(3):787-92 [1535895.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1350-5 [8339224.001]
  • [Cites] Acta Radiol. 1993 Sep;34(5):520-6 [8369193.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] Surg Neurol. 1994 Oct;42(4):335-9 [7974132.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Aug;97(3):219-28 [7586853.001]
  • [Cites] Surg Neurol. 1996 Jan;45(1):49-56 [9190699.001]
  • [Cites] J Neurosurg. 1996 May;84(5):742-7 [8622146.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):790-5 [9024717.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Cancer. 1997 May 15;79(10):1995-2002 [9149028.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):279-83 [9258819.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):155-9 [10393370.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):506-9 [10470830.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):53-9 [15719276.001]
  • [Cites] Neurosurg Rev. 2005 Apr;28(2):96-103 [15580370.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):683-8 [16163043.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):415-8 [16826361.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):286-92; discussion 292 [16604374.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):270-85; discussion 285 [16941163.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54 [17187939.001]
  • [Cites] Neuroradiology. 2007 Jul;49(7):551-4 [17364196.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • (PMID = 18022760.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS039918-03; United States / NINDS NIH HHS / NS / R01 NS039918-02; United States / NINDS NIH HHS / NS / NS039918-02; United States / NINDS NIH HHS / NS / R01 NS039918-01; United States / NINDS NIH HHS / NS / NS039918-03; United States / NINDS NIH HHS / NS / NS039918-01
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS39918; NLM/ PMC2702989
  •  go-up   go-down


55. Lázaro BC, Landeiro JA: Tectal plate tumors. Arq Neuropsiquiatr; 2006 Jun;64(2B):432-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tectal plate tumors.
  • Tectal plate is a rare location for a tumor.
  • Many papers have described different types of pathology arising in that location including tumors, vascular lesions, inflammatory and infectious processes.
  • Open surgery was performed in three cases (due to tumor enlargement or need for the exact diagnosis).
  • In our series, except in the metastatic tumor case and the cavernoma, the other types of lesion consisted of low grade gliomas.
  • These lesions represent a different type of brain stem tumor sharing a common good prognosis, with a benign behavior.
  • We believe that tectal tumors must be managed case by case.
  • When a patient presents with a benign lesions in the tectal region, treating the main symptom--hydrocephalus--should be the first attempt in management of these lesions.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Tectum Mesencephali

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917614.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


56. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


57. Jabbour SK, Zhang Z, Arnold D, Wharam MD: Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience. J Neurooncol; 2009 Jan;91(2):227-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second tumor in intracranial germinoma patients treated with radiation therapy: the Johns Hopkins experience.
  • BACKGROUND: We reviewed the risk of second tumor (ST), both malignant and benign, in germinoma survivors followed at the Johns Hopkins Hospital (JHH).
  • In the presence of competing events, a cumulative incidence function of ST was estimated using the minimal time interval from the date of diagnosis to the date of ST, date of death, or date of last follow-up.
  • One developed a benign falcine meningioma.
  • [MeSH-major] Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / epidemiology. Neoplasms, Second Primary / etiology. Radiotherapy / adverse effects. Risk
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / radiotherapy. Child. Combined Modality Therapy. Female. Follow-Up Studies. Germinoma / radiotherapy. Humans. Incidence. Male. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1532-8 [17442996.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):83-8 [16317732.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1874-8 [2556586.001]
  • [Cites] Intern Med. 2000 Nov;39(11):920-4 [11065243.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73 [10924973.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):83-5 [15527112.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):410-3 [17475364.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):453-9 [16767718.001]
  • [Cites] Neuropediatrics. 2005 Apr;36(2):71-7 [15822019.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2833-9 [17602088.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2585-92 [10561326.001]
  • [Cites] Ann Neurol. 1998 Sep;44(3):313-6 [9749596.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):723-6 [10442196.001]
  • [Cites] Urol Oncol. 2001 Mar;6(2):49-52 [11166620.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):14-21 [2536126.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2741-2; author reply 2742 [17039496.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):511-8 [12738328.001]
  • [Cites] Pediatr Blood Cancer. 2007 Sep;49(3):294-7 [17243137.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1165-70 [15001260.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):771-2 [7962639.001]
  • [Cites] Ann Oncol. 2005 May;16(5):793-7 [15802277.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):126-34 [15895370.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):846-53 [14990640.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):77-82 [16047364.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):419-26 [9308946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1171-6 [10725628.001]
  • (PMID = 18813873.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Fanburg-Smith JC, Auerbach A, Marwaha JS, Wang Z, Rushing EJ: Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases. Hum Pathol; 2010 May;41(5):653-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal chondrosarcoma, a rare malignant round cell and hyaline cartilage tumor, is most commonly intraosseous but can occur in extraskeletal sites.
  • Immunohistochemistry and follow-up were obtained on mesenchymal chondrosarcoma and tumor controls.
  • Twenty-two mesenchymal chondrosarcomas included 5 central nervous system (all female; mean age, 30.2; mean size, 7.8 cm; in frontal lobe [n = 4] and spinal cord [n = 1]) and 17 musculoskeletal (female-male ratio, 11:6; mean age, 31.1; mean size, 6.2 cm; 3 each of humerus and vertebrae; 2 each of pelvis, rib, tibia, neck soft tissue; one each of femur, unspecified bone, and elbow soft tissue).
  • The hyaline cartilage in most tumors revealed a consistent linear progression of chondrocyte morphology, from resting to proliferating to hypertrophic chondrocytes.
  • Mesenchymal chondrosarcoma demonstrates centrally located hyaline cartilage with a linear progression of chondrocytes from resting to proliferative to hypertrophic, which undergoes endochondral ossification, recapitulating growth plate cartilage and suggesting that this component of mesenchymal chondrosarcoma may be a differentiated (benign or metaplastic) component of a malignant metastasizing tumor.
  • Rare nuclear beta-catenin expression at the interface between hyaline cartilage and small round cells potentially implicates the APC/Wnt pathway during endochondral ossification in morphologically benign hyaline cartilage component of mesenchymal chondrosarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Bone and Bones / pathology. Brain Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Hyaline Cartilage / pathology. Osteocalcin / metabolism. SOX9 Transcription Factor / metabolism. beta Catenin / metabolism


59. Ondik MP, Preston T, Towfighi J, Isaacson JE: Unilateral congenital facial nerve paralysis secondary to a benign epithelioid peripheral nerve sheath tumor. Otol Neurotol; 2007 Dec;28(8):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral congenital facial nerve paralysis secondary to a benign epithelioid peripheral nerve sheath tumor.
  • OBJECTIVE: A benign epithelioid peripheral nerve sheath tumor is described in the setting of congenital facial nerve (FN) paralysis.
  • INTERVENTIONS: Auditory brainstem evoked potential study, gadolinium-enhanced magnetic resonance imaging, temporal bone computed tomography, and transmastoid FN decompression with tumor resection.
  • MAIN OUTCOME MEASURES: Follow-up for tumor recurrence and postoperative FN function.
  • RESULTS: The child underwent a transmastoid FN exploration with resection of a 0.6-cm spherical tumor analyzed to be a benign epithelioid peripheral nerve sheath tumor.
  • CONCLUSION: Benign epithelioid peripheral nerve sheath tumor can cause congenital facial nerve palsy.
  • [MeSH-major] Facial Nerve Diseases / congenital. Facial Nerve Diseases / etiology. Neoplasms, Glandular and Epithelial / complications. Neoplasms, Glandular and Epithelial / congenital. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / congenital
  • [MeSH-minor] Decompression, Surgical. Evoked Potentials, Auditory, Brain Stem / physiology. Facial Nerve / physiology. Facial Paralysis / congenital. Facial Paralysis / etiology. Female. Gadolinium. Humans. Infant. Magnetic Resonance Imaging. Temporal Bone / radiography

  • Genetic Alliance. consumer health - paralysis.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084823.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


60. Lu Q, Dobbs LJ, Gregory CW, Lanford GW, Revelo MP, Shappell S, Chen YH: Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol; 2005 Oct;36(10):1037-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • delta-Catenin, or neural plakophilin-related armadillo protein, is a unique armadillo domain-containing protein in that it is neural-specific and primarily expressed in the brain.
  • The analyses of 90 human prostate cancer and 90 benign prostate tissue samples demonstrated that an estimated 85% of prostatic adenocarcinomas showed enhanced delta-catenin immunoreactivity. delta-Catenin expression increased with prognostically significant increased Gleason scores.
  • By analyzing the same tumor cell clusters using consecutive sections, we showed that an increased delta-catenin immunoreactivity was accompanied by the down-regulation and redistribution of E-cadherin and p120ctn, major cell junction proteins whose inactivation is frequently associated with cancer progression.
  • [MeSH-major] Armadillo Domain Proteins / metabolism. Cadherins / metabolism. Cell Adhesion Molecules / metabolism. Cytoskeletal Proteins / metabolism. Down-Regulation. Phosphoproteins / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Blotting, Western. Bone Marrow Cells / cytology. Catenins. Cell Line, Tumor. Cells, Cultured. Epithelial Cells / cytology. Epitopes. Fluorescent Antibody Technique. Green Fluorescent Proteins / metabolism. Humans. Immunohistochemistry. Male. Microarray Analysis. PC12 Cells. Precipitin Tests. Prognosis. Prostate / cytology. Radioimmunoassay. Rats. Stromal Cells / cytology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226102.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Armadillo Domain Proteins; 0 / Cadherins; 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Cytoskeletal Proteins; 0 / Epitopes; 0 / Phosphoproteins; 0 / delta catenin; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


61. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res; 2005 Aug 1;65(15):6726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
  • Malignant gliomas are deadly brain tumors characterized by diffuse invasion into the surrounding brain tissue.
  • Here we describe for the first time the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms, B/b(sia) and B/b(Deltag), which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies.
  • In addition, its absence from benign gliomas prompts its use as a diagnostic marker to distinguish primary brain tumors of similar histology but different pathologic course.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioma / metabolism. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01/NS35228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Brevican; 0 / Carrier Proteins; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


62. Korshunov A, Cherekaev V, Bekyashev A, Sycheva R: Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J Neurooncol; 2007 Jan;81(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region.
  • Mean number of aberrations detected per tumor was significantly greater for invasive meningiomas-67.4 compared with 40.5 for non-invasive MSR.
  • Thus, the presence of a complex cytogenetic profile and progression-associated chromosomal aberrations in benign MSR is associated with their increased invasive potential.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics. Sphenoid Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2004;21(1):27-34 [15696966.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Surg Neurol. 2005 Jul;64(1):37-43; discussion 43 [15993178.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):59-63 [14756442.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):869-80 [14871962.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1079-86 [12204057.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):256-65 [15009703.001]
  • [Cites] Brief Funct Genomic Proteomic. 2003 Apr;2(1):37-45 [15239942.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):465-74 [16557391.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):742-6; discussion 746-7 [10201298.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Am J Clin Pathol. 2001 Feb;115(2):213-8 [11211609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):145-53 [11958368.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):747-54 [16197812.001]
  • [Cites] J Oral Pathol Med. 2006 Mar;35(3):136-9 [16454808.001]
  • [Cites] Neuro Oncol. 2004 Oct;6(4):281-9 [15494095.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • (PMID = 16850103.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Tuniz F, Soltys SG, Choi CY, Chang SD, Gibbs IC, Fischbein NJ, Adler JR Jr: Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study. Neurosurgery; 2009 Nov;65(5):898-907; discussion 907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multisession cyberknife stereotactic radiosurgery of large, benign cranial base tumors: preliminary study.
  • OBJECTIVE: Although radiosurgery plays an important role in managing benign cranial base lesions, the potential for increased toxicity with single-session treatment of large tumors is a concern.
  • In this retrospective study, we report the intermediate-term rate of local control, morbidity, and clinical outcomes of patients with large cranial base tumors treated with multisession stereotactic radiosurgery with the CyberKnife (Accuray, Inc., Sunnyvale, CA).
  • METHODS: Between 1999 and 2008, 34 consecutive patients with large (>15 cm), benign cranial base tumors (21 meningiomas, 9 schwannomas, 4 glomus jugulare tumors) underwent primary or postoperative radiosurgical treatment using a multisession approach at Stanford University and were considered in this retrospective study.
  • CyberKnife radiosurgery was delivered in 2 to 5 sessions (median, 3 sessions) to a median tumor volume of 19.3 cm (range, 15.8-69.3 cm).
  • To date, all tumors remain locally controlled.
  • CONCLUSION: Over our modest length of follow-up, multisession radiosurgery appears to be a safe and effective option for selected large, benign brain and cranial base lesions.
  • [MeSH-major] Radiosurgery / methods. Skull Base Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834402.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


64. Nagesh V, Tsien CI, Chenevert TL, Ross BD, Lawrence TS, Junick L, Cao Y: Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1002-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study.
  • PURPOSE: To quantify the radiation-induced changes in normal-appearing white matter before, during, and after radiotherapy (RT) in cerebral tumor patients.
  • METHODS AND MATERIALS: Twenty-five patients with low-grade glioma, high-grade glioma, or benign tumor treated with RT were studied using diffusion tensor magnetic resonance imaging.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Aug;236(2):647-52 [16040920.001]
  • [Cites] J Head Trauma Rehabil. 2003 Jul-Aug;18(4):307-16 [16222127.001]
  • [Cites] Magn Reson Med. 2006 Feb;55(2):302-8 [16408263.001]
  • [Cites] J Neurosci Res. 2006 Feb 15;83(3):392-402 [16397901.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):884-90 [16484697.001]
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] Eur J Neurol. 2007 May;14(5):540-7 [17437614.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 [17306935.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):51-5 [10656372.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):101-11 [10780628.001]
  • [Cites] Radiat Res. 2000 Apr;153(4):357-70 [10798963.001]
  • [Cites] Magn Reson Med. 2000 Aug;44(2):259-68 [10918325.001]
  • [Cites] J Med Primatol. 2001 Apr;30(2):81-7 [11491408.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Oct;82(10):1461-71 [11588754.001]
  • [Cites] Radiology. 2001 Nov;221(2):349-58 [11687675.001]
  • [Cites] Radiother Oncol. 2002 Apr;63(1):107-20 [12065111.001]
  • [Cites] Neuroimage. 2002 Nov;17(3):1429-36 [12414282.001]
  • [Cites] Neuroimage. 2003 Nov;20(3):1714-22 [14642481.001]
  • [Cites] Acta Neuropathol. 1968 Nov 1;11(4):267-74 [5710040.001]
  • [Cites] Cancer. 1979 Oct;44(4):1256-72 [387205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1966-72 [6478431.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):635-40 [3731021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):319-30 [2841263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1371-81 [2461919.001]
  • [Cites] Br J Radiol. 1988 Nov;61(731):1043-52 [3208008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):37-42 [2298633.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):689-96 [2004945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):1089-91; discussion 1093-4 [1639645.001]
  • [Cites] Radiother Oncol. 1993 Oct;29(1):60-8 [8295989.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2828-35 [7954244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Brain Res. 1995 Feb 6;671(1):141-8 [7728526.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan;12(1):45-62 [7502957.001]
  • [Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]
  • [Cites] Magn Reson Med. 1996 Dec;36(6):893-906 [8946355.001]
  • [Cites] Magn Reson Med. 1998 Jun;39(6):928-34 [9621916.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):480-4 [10201420.001]
  • [Cites] Brookhaven Symp Biol. 1961 Nov;14:176-99 [14010110.001]
  • [Cites] J Neurol Sci. 2005 Mar 15;229-230:195-200 [15760639.001]
  • [Cites] Neuroimage. 2005 May 15;26(1):132-40 [15862213.001]
  • (PMID = 18313524.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113699-02; United States / NCI NIH HHS / CA / R21 CA113699; United States / NCI NIH HHS / CA / R21 CA113699-02; United States / NCI NIH HHS / CA / P01 CA059827; United States / NCI NIH HHS / CA / 3P01 CA59827; United States / NCI NIH HHS / CA / CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878-01A2; United States / NCI NIH HHS / CA / P02 CA85878; United States / NCI NIH HHS / CA / P01 CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / R21 CA11369901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS42273; NLM/ PMC2376211
  •  go-up   go-down


65. Samaila MO, Mbibu HN, Oluwole OP: Human mycetoma. Surg Infect (Larchmt); 2007 Oct;8(5):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the disease may present without these characteristic features, thus causing diagnostic difficulty with other chronic granulomatous infections such as tuberculosis or benign skin lesions.
  • The range of clinical misdiagnoses included skin tuberculosis, fibroma, amelanotic melanoma, basal-cell carcinoma, and brain tumor.
  • Knowledge of mycetoma pathology is important for prompt diagnosis and treatment of this indolent clinical entity.
  • [MeSH-major] Mycetoma / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycetoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999585.001).
  • [ISSN] 1096-2964
  • [Journal-full-title] Surgical infections
  • [ISO-abbreviation] Surg Infect (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Schittenhelm J, Ebner FH, Harter P, Bornemann A: Symptomatic intraspinal oncocytic adrenocortical adenoma. Endocr Pathol; 2009;20(1):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most intraspinal neoplasms of epithelial origin are metastases from primary carcinomas.
  • Benign epithelial tumors are rarely found at this site.
  • The excised tumor was composed of nests of large polygonal cells with eosinophilic partial granular cytoplasm.
  • The tumor showed diffuse positivity for melan-A, synaptophysin, and alpha-inhibin.
  • Ultrastructural examination showed abundant mitochondria, suggesting an oncocytic tumor.
  • The diagnosis of an oncocytic adrenal cortical adenoma was made.
  • These extraadrenal tumors are thought to arise from heterotopic adrenocortical tissue in the spinal cavity.
  • Oncocytic tumors are rare neoplasms and they comprise non-functioning variants of adrenal cortical adenomas.
  • To date, only five such intraspinal tumors have been observed.
  • Immunohistochemistry excluded oncocytic paraganglioma, oncocytic meningioma, renal cell carcinoma, alveolar soft part sarcoma, and granular cell tumor.
  • A view of the literature of these rare but probably underdiagnosed intraspinal tumors is given.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenocortical Adenoma / pathology. Spinal Cord Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Radiol. 2005 Sep;60(9):953-9 [16124976.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):260-5 [12053045.001]
  • [Cites] Spinal Cord. 2007 Feb;45(2):183-6 [16505829.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):57-63 [9422316.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):259-64 [15306940.001]
  • [Cites] J Neurosurg. 2001 Apr;94(2 Suppl):310-2 [11302638.001]
  • [Cites] J Pediatr Surg. 1980 Jun;15(3):289-92 [6103925.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):E1144; discussion E1144 [17143207.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):658-61; discussion 661-2 [8474656.001]
  • [Cites] Histopathology. 1997 Aug;31(2):167-73 [9279569.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 15;233(1-2):47-56 [15767045.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):375-82 [9130983.001]
  • [Cites] J Med Case Rep. 2008 Jul 13;2:228 [18620603.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):481-4 [2327553.001]
  • [Cites] Histopathology. 1986 Mar;10(3):311-9 [2422107.001]
  • [Cites] Fetal Pediatr Pathol. 2006 Jul-Aug;25(4):191-7 [17162526.001]
  • [Cites] J Clin Pathol. 1998 Feb;51(2):114-6 [9602683.001]
  • [Cites] AMA Arch Pathol. 1959 Feb;67(2):228-33 [13616833.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):756-9 [10981764.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • (PMID = 19039533.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Kars M, Roelfsema F, Romijn JA, Pereira AM: Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol; 2006 Oct;155(4):523-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, the initial clinical, biochemical, and histological characteristics are of minimal utility in distinguishing benign adenomas from pituitary carcinomas.
  • In brief, it is postulated that pituitary carcinomas arise from the transformation of initially large, but benign, adenomas.
  • In vivo, the development of dopamine agonist resistance in invasive macroprolactinoma is indicative of malignancy and should prompt the clinician to perform a biopsy of the tumor.
  • For pituitary tumors that exhibit high mitotic activity, increased Ki-67 and/or p53 immunoreactivity, it may be useful to denote these tumors as 'atypical' prolactinomas to raise the possibility of future malignant development.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990651.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Pyrrolidines; 107188-87-4 / epidepride; 9002-62-4 / Prolactin
  • [Number-of-references] 47
  •  go-up   go-down


68. Teo C, Broggi M: Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neuro-oncological multidisciplinary teams. Childs Nerv Syst; 2010 Sep;26(9):1219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neuro-oncological multidisciplinary teams.
  • PURPOSE: Despite the lack of evidence in literature, it is widely felt that patient outcomes will be improved by adopting a multidisciplinary team (MDT) approach to children with brain tumors.
  • METHODS: A retrospective study was conducted on all pediatric brain and spinal cord tumor patients operated in a single center from 1999 to 2009.
  • Details of preoperative treatment, diagnosis and clinical status, postoperative diagnosis, early and late outcomes, progression-free survival and overall survival, and parental satisfaction were reviewed.
  • In ten cases, radical removal of the tumor resulted in a change in histological diagnosis, usually from a presumed diagnosis of malignancy to a more benign variety (n = 6).
  • [MeSH-major] Adenoma / surgery. Brain Neoplasms / surgery. Glioma / surgery. Salvage Therapy. Spinal Cord Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Childs Nerv Syst. 2010 Sep;26(9):1227-8 [20574741.001]
  • [ErratumIn] Childs Nerv Syst. 2010 Dec;26(12):1833. Charles, Teo [corrected to Teo, Charles]; Morgan, Broggi [corrected to Broggi, Morgan]
  • [Cites] Curr Neurol Neurosci Rep. 2001 Mar;1(2):137-43 [11898509.001]
  • [Cites] Breast J. 2004 Sep-Oct;10(5):469-72 [15327510.001]
  • [Cites] BMJ. 1996 Jan 20;312(7024):145-8 [8563532.001]
  • [Cites] J Neurooncol. 2009 May;92(3):275-82 [19357955.001]
  • [Cites] Breast. 2006 Feb;15(1):119-22 [16473745.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):49-63 [15701282.001]
  • [Cites] BMJ. 1996 May 4;312(7039):1155-6 [8620140.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):979-85 [17047646.001]
  • [Cites] Oncologist. 2007 Jul;12(7):884-98 [17673619.001]
  • [Cites] Breast J. 2003 Jan-Feb;9(1):60-3 [12558678.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):274-82 [11452935.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2005 Jul;35(6):230-45 [15956960.001]
  • [Cites] Neurosurgery. 2004 Mar;54(3):553-63; discussion 563-5 [15028128.001]
  • [Cites] Cancer. 1978 Jan;41(1):29-35 [626937.001]
  • [Cites] Acta Neurochir (Wien). 2009 Feb;151(2):109-12 [19194651.001]
  • [Cites] Oncology (Williston Park). 2004 Sep;18(10):1263-8; discussion 1268-70, 1275 [15526830.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2480-91 [16904313.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):505-33 [10836005.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):160-6 [11307058.001]
  • [Cites] Pediatr Clin North Am. 1985 Jun;32(3):633-51 [3889800.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):152-62 [11285553.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13):1649-61; discussion 1662, 1665-6, 1668 [15648297.001]
  • (PMID = 20563727.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Albers AC, Gutmann DH: Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother; 2009 Apr;9(4):535-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 (NF1) is an inherited autosomal dominant disorder characterized by numerous cutaneous features, including café-au-lait macules, skinfold freckling and iris hamartomas.
  • In addition, individuals with NF1 are prone to the development of both benign and malignant tumors.
  • The most common CNS tumor in children and adults with NF1 is the glioma.
  • Regular ophthalmologic evaluations in children are essential for the effective management of these tumors in patients with NF1.
  • [MeSH-major] Brain Neoplasms / complications. Glioma / complications. Neurofibromatosis 1 / complications


70. Zhou GF, Wang XY, Huang MP: [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [BOLD-fMRI in sensory area and motor hand functional area with brain tumor in the central area].
  • OBJECTIVE: To explore the geomorphological performance, the characteristics of volume, and the largest signal intension of blood oxygenation level dependent functional magnetic resonance imaging (BOLD-fMRI) in brain tumors located in or closed to the central area.
  • METHODS: We recruited 13 normal volunteers and 31(13 benign tumors and 18 malignant tumors) patients with brain tumor located in or closed to the central area, to examine both side hand motor and tactile function by BOLD-fMRI and obtained the activation map and its superposition image with T1 imaging, the volume, and the largest signal intension of the functional area by SPM software which manipulated the raw data in the off-line work station.
  • There was difference in the activated signal pixel number and the largest signal intension of the functional area between the benign brain tumors, malignant brain tumors, and the normal volunteers (P < 0.05).
  • The shape, anatomic location, the volume, and the largest signal intension of the functional area were changed in the patients with brain tumors.
  • CONCLUSION: BOLD-fMRI is a valid method to assess the pre-surgical risk of patients with brain tumors, which can get the volume, the largest signal intension, the basic shape,and the anatomic location of the functional area.
  • [MeSH-major] Brain Neoplasms / physiopathology. Hand / physiopathology. Magnetic Resonance Imaging / methods. Motor Cortex / physiopathology. Somatosensory Cortex / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667768.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


71. McClelland S 3rd, Long DM: Genesis of the use of corticosteroids in the treatment and prevention of brain edema. Neurosurgery; 2008 Apr;62(4):965-7; discussion 967-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genesis of the use of corticosteroids in the treatment and prevention of brain edema.
  • Galicich, French, and Melby describing the use of dexamethasone for peritumoral cerebral edema, the use of corticosteroids in patients with brain tumors has become routine.
  • METHODS: During a pilot study to assess corticosteroid uptake in brain tumors, Dr.
  • Galicich observed that patients given a large dose of corticosteroids just before craniotomy had a relatively benign postoperative course.
  • This finding prompted the studies that confirmed the efficacy of high-dose corticosteroids in reducing peritumoral brain edema in humans reported in the 1961 article.
  • RESULTS: After publication, a revolution in brain tumor management occurred because corticosteroid therapy markedly reduced the morbidity and mortality associated with brain tumors both in the United States and worldwide.
  • [MeSH-major] Adrenal Cortex Hormones / history. Adrenal Cortex Hormones / therapeutic use. Brain Edema / history. Brain Edema / prevention & control. Physicians / history

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496203.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


72. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


73. Sadetzki S, Chetrit A, Freedman L, Stovall M, Modan B, Novikov I: Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. Radiat Res; 2005 Apr;163(4):424-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.
  • Ionizing radiation is an established risk factor for brain tumors, yet quantitative information on the long-term risk of different types of brain tumors is sparse.
  • Our aims were to assess the risk of radiation-induced malignant brain tumors and benign meningiomas after childhood exposure and to investigate the role of potential modifiers of that risk.
  • The mean estimated radiation dose to the brain was 1.5 Gy.
  • Survival analysis using Poisson regression was performed to estimate the excess relative and absolute risks (ERR, EAR) for brain tumors.
  • After a median follow-up of 40 years, an ERR/Gy of 4.63 and 1.98 (95% CI = 2.43-9.12 and 0.73-4.69) and an EAR/Gy per 10(4) PY of 0.48 and 0.31 (95% CI = 0.28-0.73 and 0.12-0.53) were observed for benign meningiomas and malignant brain tumors, respectively.
  • The risk of both types of tumors was positively associated with dose.
  • The estimated ERR/Gy for malignant brain tumors decreased with increasing age at irradiation from 3.56 to 0.47 (P = 0.037), while no trend with age was seen for benign meningiomas.
  • The ERR for both types of tumor remains elevated at 30-plus years after exposure.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Radiotherapy / statistics & numerical data. Risk Assessment / methods. Tinea Capitis / epidemiology. Tinea Capitis / radiotherapy


74. Zhao YC, Li NY, Zhou XJ, Zhou HB, Ma HH, Zhang RS: [Clinicopathologic study of pilocytic astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Sep;37(9):609-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic degeneration was noted in 41 cases (60.3%), and enhancement of the tumor was noted in 43 cases (87.8%).
  • Total tumor excision was performed in 35 patients, subtotal tumor excision was performed in 31 patients, and the procedures of other 2 patients were not clear.
  • Among 51 patients with follow-up information, 44 were alive, 7 had recurrent tumor, and 7 died.
  • Tumors with classic histopathology demonstrated biphasic pattern of growth, consisting of compact elongated bipolar astrocytes associated with rosenthal fibers, and less cellular areas of multipolar cells with granular bodies and microcyst.
  • All cases showed diffuse positive staining for GFAP and low expression for Ki-67, except 1 anaplastic tumor with 10% Ki-67 indices.
  • Tumors with subarachnoid space involvement showed positive reticular fiber staining and negative EMA staining.
  • CONCLUSIONS: PA is a benign, WHO grade I tumor with favorable prognosis, and does not require radiotherapy after total resection.
  • The tumor can be mistaken as higher-grade astrocytoma when involving the subarachnoid space, and with cytological atypia, leading to unnecessary radiotherapy after surgery.
  • The outcome for patients with brainstem tumor or anaplastic PA is poor.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glial Fibrillary Acidic Protein / genetics. Recurrence

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094585.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


75. Caffo M, Caruso G, Galatioto S, Meli F, Cacciola F, Germanò A, Alafaci C, Tomasello F: Immunohistochemical study of the extracellular matrix proteins laminin, fibronectin and type IV collagen in secretory meningiomas. J Clin Neurosci; 2008 Jul;15(7):806-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory meningiomas are rare histological meningioma subtypes that have benign behavior, are highly vascularized and are frequently accompanied by massive peritumoral edema.
  • Meningiomas increase in size through increased production of extracellular matrix; furthermore, the proliferation of cells typically associated with neoplasia requires considerable interaction with the extracellular matrix.
  • [MeSH-major] Brain Neoplasms / metabolism. Extracellular Matrix / metabolism. Extracellular Matrix Proteins / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / physiopathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Proliferation. Collagen Type IV / metabolism. Fibronectins / metabolism. Humans. Immunohistochemistry. Laminin / metabolism. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474427.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Extracellular Matrix Proteins; 0 / Fibronectins; 0 / Laminin
  •  go-up   go-down


76. Shingu T, Akiyama Y, Daisu M, Maruyama N, Matsumoto Y, Miyazaki T, Nagai H, Yamamoto Y, Yamasaki T, Yoshida M, Maruyama R, Moritake K: Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):222-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and T(2)*-weighted magnetic resonance imaging revealed hemorrhage in the tumor located in the right basal ganglia, thalamus, and hypothalamus.
  • Although neither symptomatic hemorrhage nor late benign recurrence is common, careful long-term follow up is necessary for patients with pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527050.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Gallina P, Buccoliero AM, Mariotti F, Mennonna P, Di Lorenzo N: Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course. J Neurosurg; 2006 Nov;105(5):736-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course.
  • OBJECT: Oncocytic meningioma has recently been recognized as a distinct morphological variant of intracranial meningothelial neoplasms, and only a few cases have been reported in the literature.
  • The first description of this lesion, which was based on data in six cases, revealed a potentially aggressive nature with a tendency to infiltrate the brain and to recur.
  • Histologically, the tumors were composed of sheets, nests, and cords of large polygonal neoplastic cells with finely granular cytoplasm.
  • Mitosis was also absent or exceedingly rare, and no brain cortex infiltration was observed.
  • At the last follow-up evaluation, all patients were asymptomatic and magnetic resonance imaging examinations demonstrated no evidence of tumor recurrence.
  • In fact, the histological features as well as the long-term favorable clinical course may suggest benign behavior of such neoplasms, as in the common forms of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Oxyphil Cells / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121136.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


78. Mainio A, Tuunanen S, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci; 2006 Dec;256(8):516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To assess the long-term survival of brain tumor patients, and in particular to evaluate the relation of quality of life (QOL) to survival among low-grade glioma patients.
  • METHODS: The postoperative survival of 101 brain tumor patients was followed from surgery (1990-1992) until the end of the year 2003.
  • RESULTS: The mean survival times in years (SD) were significantly related to tumor malignancy, being the shortest, 1.9 (0.6), for patients with high-grade gliomas, while patients with low-grade gliomas or a benign brain tumor had mean survival times of 9.1 (1.0) and 11.6 (0.5), respectively.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / psychology. Depressive Disorder / mortality. Depressive Disorder / psychology. Glioma / mortality. Glioma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Aged. Disease Progression. Dominance, Cerebral / physiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications / mortality. Postoperative Complications / psychology. Prognosis. Statistics as Topic. Survival Analysis


79. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS: Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery; 2007 Apr;60(4):750-9; discussion 759-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The lack of meningioma models has hindered research on the pathogenesis and treatment of this commonly diagnosed primary brain tumor.
  • Animal models of meningioma have been difficult to develop, especially those derived from Grade I tumors, which display very slow growth rates, senesce at early passages, and infrequently survive as explants in vivo.
  • In this study, the authors report the establishment of two benign immortalized meningioma cell lines, Me10T and Me3TSC, that can serve as useful models of human meningioma.
  • In addition, immortalized cell lines were implanted subdurally into mice to confirm their ability to form tumors.
  • RESULTS: Two immortalized benign meningioma cell lines, Me10T and Me3TSC, transduced with catalytic subunit human telomerase reverse transcriptase alone or human telomerase reverse transcriptase and SV40 large T antigen, were established.
  • After subdural injection into athymic nude mice, both cell lines formed identifiable tumors with histological features and immunostaining patterns of human meningioma.
  • [MeSH-major] Cell Line, Tumor / enzymology. Cell Line, Tumor / pathology. Cell Transformation, Neoplastic / genetics. Meningioma / enzymology. Meningioma / genetics. Telomerase / genetics. Transfection / methods

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415213.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


80. Alkan O, Yildirim T, Kizilkiliç O, Tan M, Cekinmez M: A case of ecchordosis physaliphora presenting with an intratumoral hemorrhage. Turk Neurosurg; 2009 Jul;19(3):293-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ecchordosis physaliphora is a rare congenital, benign, hamartomatous, retroclival mass derived from notochordal tissue that is typically located intradurally in the prepontine cistern.
  • In rare cases, ecchordosis physaliphora can be symptomatic due to tumor expansion and compression of the surrounding structures and extratumoral hemorrhage.
  • [MeSH-major] Brain Diseases / etiology. Hamartoma / complications. Notochord / pathology. Subarachnoid Hemorrhage / etiology

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621298.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; R16CO5Y76E / Aspirin
  •  go-up   go-down


81. Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O, Inoue T: Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate; 2010 Jun 1;70(8):866-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ras homolog-enriched in brain (Rheb), a small GTP-binding protein, is associated with prostate carcinogenesis through activating mammalian target of rapamycin (mTOR) signaling pathway.
  • Rheb expression was higher in cancer tissues than in benign prostatic epithelia.
  • [MeSH-major] Cell Cycle / physiology. Intracellular Signaling Peptides and Proteins / metabolism. Monomeric GTP-Binding Proteins / metabolism. Neuropeptides / metabolism. Prostate / metabolism. Prostatic Neoplasms / metabolism. Protein-Serine-Threonine Kinases / metabolism. Receptors, Androgen / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Blotting, Western. Cell Count. Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. Immunohistochemistry. Male. Prostatic Hyperplasia / genetics. Prostatic Hyperplasia / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20127734.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Neuropeptides; 0 / RHEB protein, human; 0 / RNA, Messenger; 0 / Receptors, Androgen; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins
  •  go-up   go-down


82. Pascual Castroviejo I, Pascual Pascual S, Velázquez Fragua R, Viaño J, Garcia Segura JM: [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients]. Neurologia; 2007 Dec;22(10):846-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain stem tumors associated with neurofibromatosis type 1. Presentation of 20 infantile patients].
  • [Transliterated title] Tumores de tronco cerebral asociados con neurofibromatosis tipo 1. Presentación de 20 pacientes infantiles.
  • OBJECTIVE: To describe the clinical and imaging findings of 20 patients (12 women and 8 men) with brain stem tumors associated with neurofibromatosis type 1 (NF1).
  • Thirteen of the 20 patients (65 %) also had optic pathway tumor.
  • Brain stem tumor identification occurred at the same time as NF1 in the patients who were studied by MR at the time of the first consult.
  • RESULTS: Brain stem identification occurred at the same time as that of the NF1 in patients who were studied by MR from the beginning.
  • Diffuse or localized medullary enlargement was the most frequent MR imaging and appeared in 13 patients (65%), followed by the tumor that involved all brain stem (pontine and medullary areas) that appeared in 6 patients (30 %).
  • In the last group, one tumor showed extension through brain stem and medial cerebellar parts, another was located in the aqueduct and in the periaqueductal areas and showed slow progressive growth, and one third patient had a tumor with aggressive signs in the SMR study.
  • Another patient had an aggressive tumor that involved the left optic nerve, chiasm, mesencephalon and upper right pontine areas.
  • The histological study of the tumoral biopsic tissue of the two last patients showed astrocitoma degree 1 (benign tumor).
  • The two aggressive tumors were treated with radiotheraphy and chemotherapy and they are still alive 4 and 7 years respectively after treatment.
  • Only one of the 20 patients died, although it was due to a malignant chiasmatic tumor, that had been treated twenty years before, and not by the brain stem tumor.
  • CONCLUSIONS: In NF1, brain stem tumors are the most frequent tumors of the posterior fossa and the second most frequent of the central nervous system (CNS).
  • MR and SMR are necessary to a correct identification of the tumor in some patients.
  • Most of these tumors are benign.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Brain Stem. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Neurofibromatosis 1 / complications


83. Waltereit R, Welzl H, Dichgans J, Lipp HP, Schmidt WJ, Weller M: Enhanced episodic-like memory and kindling epilepsy in a rat model of tuberous sclerosis. J Neurochem; 2006 Jan;96(2):407-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TSC starts in early childhood and is characterized by cerebral hamartomas (benign tumours), severe epilepsy and cognitive deficits such as mental retardation and autism.
  • The hamartomas are characterized by loss of the remaining wild-type TSC allele, and clinical data implicate cerebral hamartomas in the generation of epileptic seizures, which may play a significant role in the development of mental retardation.
  • We therefore hypothesized that the heterozygous mutation itself, besides cerebral hamartomas, contributes to the pathogenesis of cognitive deficits and possibly also epilepsy.
  • Here, we show that young adult TSC2+/- rats, which are virtually free of cerebral hamartomas, exhibit enhanced episodic-like memory and enhanced responses to chemically-induced kindling.
  • [MeSH-major] Epilepsy / etiology. Kindling, Neurologic. Memory, Short-Term. Mutation. Tuberous Sclerosis / genetics. Tuberous Sclerosis / psychology. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epilepsy Curr. 2006 Nov-Dec;6(6):210-2 [17260062.001]
  • (PMID = 16300636.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1
  •  go-up   go-down


84. Miller SJ, Jessen WJ, Mehta T, Hardiman A, Sites E, Kaiser S, Jegga AG, Li H, Upadhyaya M, Giovannini M, Muir D, Wallace MR, Lopez E, Serra E, Nielsen GP, Lazaro C, Stemmer-Rachamimov A, Page G, Aronow BJ, Ratner N: Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med; 2009 Jul;1(4):236-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics.
  • We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6).